# CURRICULUM VITAE

## PERSONAL DATA


| | |
|---|---|
| Name: | **Bernard A. Fox, Ph.D.** |
| Phone: | 503-215-6311 |
| E-mail: | foxb@foxlab.org |


## EDUCATION

| | |
|---|---|
| Undergraduate: | University of Detroit, 1971-1975, B.S. |
| Graduate/Professional: | University of Detroit, 1975-1978, M.S.<br>Wayne State University, 1979-1985, Ph.D |

## POSTDOCTORAL TRAINING

| | |
|---|---|
| Staff Fellow: | Surgery Branch, Division of Cancer Treatment, Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 1985-1987 |
| Senior Staff Fellow: | Surgery Branch, Division of Cancer Treatment, Clinical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD 1987-1990 |

## APPOINTMENTS

| | |
|---|---|
| Instructor, Department of Surgery, University of Michigan, Ann Arbor, MI 48109 | 1990-1994 |
| Chief, Laboratory of Molecular and Tumor Immunology, and Associate Member, Earle A. Chiles Research Institute. Providence Portland Medical Center, Portland, OR 97213 | 1994-current |
| Associate Professor, Molecular Microbiology and Immunology, Oregon Health Science University School of Medicine, Portland, Oregon 97201 | 1994-current |
| Associate Professor, Environmental and Biomolecular Systems, Oregon Graduate Institute of Science and Technology, Oregon | 1995-2012 |
| Guest Professor (sabbatical), Chirurgische Klinik und Poliklinik, Klinikum Großhadern, Ludwig Maximilians Universität, München, Germany | 2001-2002 |
| Guest Professor, Xian Jiaotung University, Xian, China | 2001-2010 |
| Harder Family Chair and Member, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute | 2012-current |
| Visiting Professor, National Taiwan University College of Medicine, Graduate Institute of Oncology | 2018-current |

## CONSULTING POSITIONS

Member, University of Michigan Cancer Center, 1990-1994

Member, Oregon Cancer Center/OHSU Knight Cancer Institute, Oregon Health and Science University, 1994-current

Leader/Co-Leader, Tumor Immunology Focus Panel, OHSU Knight Cancer Institute, 2005-current

## BIOTECHNOLOGY ACTIVITIES

Board of Directors, NeoPharm, Lake Forest, IL, 2004-2010
Co-Founder, President and CEO, UbiVac, www.ubivac.com, Portland, OR, 2005-current
Co-Founder and member of Board of Directors, UbiVac CMV, Portland, OR, 2011-current
Board of Directors, Oregon Bioscience Association, https://www.oregonbio.org/ 2014-2019

## HONORS AND AWARDS

Travel Grant, American Association of Immunology, Seventh International Immunology Congress, Berlin, Germany, 1989
Science Recognition Award for New Investigators, Clinical Immunology Society, 1990
Guest Professor Award, Der Deutsche Akademische Austausch Dienst (DAAD), 2001
Sabbatical Award, Chiles Foundation, 2001
Board of Directors, International Society for Biological Therapy 2002-2005
Secretary/Treasurer, International Society for the Biological Therapy of Cancer (iSBTc), 2005-2006
Vice-President, International Society for the Biological Therapy of Cancer, 2006-2008
President, Society for Immunotherapy of Cancer (previously, International Society for the Biological Therapy of Cancer), 2008-2010
Spirit of Emilie (Gamelin) Mission Inspiration Award, Providence Health System, 2009
Immediate past President, Society for Immunotherapy of Cancer, 2010-2012
Chair, World Immunotherapy Council (WIC) 2011 – current
Ambassador, Society for Immunotherapy of Cancer, 2012-current
Visionary/Legacy Award, Society for Immunotherapy of Cancer 30th Anniversary Meeting, 2015

## SCIENTIFIC ACTIVITIES

Senior Research Assistant, Section of Surgical Research, Department of Surgery, Henry Ford Hospital, Detroit, Michigan, 1978-1980.
Director of Immunological Studies, Division of Transplantation, Department of Surgery, Henry Ford Hospital, Detroit, Michigan, 1980-1982.
Graduate Research Asst., Department of Biology, Wayne State University, Detroit, Michigan, 1982-1985.
Senior Research Assistant, Section of Surgical Research, Department of Surgery, Henry Ford Hospital, Detroit, Michigan, 1983-1985.
Consultant, Department of Urology, Wayne State University, School of Medicine, 1988
Reviewer, Alberta Cancer Board Research Initiative Program, 1990
Reviewer, Oncology Merit Review Board, Veterans Administration, 1991-1993, 1997-1999
Ad Hoc Reviewer, Cancer Research, Journal of Immunology, Proc. National Academy of Sciences, Journal of Immunotherapy, Human Gene Therapy, Cancer Gene Therapy
Member, Human applications laboratory (HAL) committee, University of Michigan, 1993
Member, Biological Therapy Subcommittee, Oregon Cancer Center, 1994- present
Member, Institutional Animal Care and Use Committee (IACUC), Earle A. Chiles Research Institute, Providence Portland Medical Center, 1994- 2007
Member, Institutional Biosafety Committee (IBC), Earle A. Chiles Research Institute, Providence Portland Medical Center, 1994- present
Chairperson, Institutional Animal Care and Use Committee (IACUC), Earle A. Chiles Research Institute, Providence Portland Medical Center, 1995- 2001

Member and Coordinator, Tumor Vaccine and Cell Therapy Working Group, 1995- present
Member, Experimental Therapy Subcommittee, Oregon Cancer Center, 1995-present
Reviewer, FDA site visit, Division of Cell and Gene Therapies, CBER, FDA, 1996
Chairperson, Institutional Biosafety Committee (IBC), Earle A. Chiles Research Institute, Providence Portland Medical Center, 1998-2000
Reviewer, Ohio Cancer Research Associates 1998-1999
Reviewer, Dutch Cancer Society, Amsterdam, The Netherlands 1998, 2001
Reviewer, Human Immunology Study Section, NIAID, NIH 1998
Reviewer, Experimental Therapeutics II Study Section, NCI, NIH, 1999-2002
Reviewer, The Wellcome Trust, London, UK 1999
Reviewer, NCI, NIH site visit, Rockefeller University/Baylor, Memorial Sloan Kettering, 1999
Reviewer, NCI, NIH PO1 review, University of Pittsburgh, 1999
Editorial Board, Current Molecular Medicine, 2000-current
Consultant, Vaccine Subcommittee, Gynecologic Oncology Group/GOG 2000
Reviewer, NCI, NIH PO1 review, Rockefeller University/Baylor, Memorial Sloan Kettering, 2000
Reviewer, NCI, NIH, Breast Cancer Triage Review Committee B 2000
Editorial Board, Cellular Immunology, 2000-current
Consultant, External Advisory Committee, Vaccines for cancer (Program project -PO1), University of Michigan, Ann Arbor, MI. 2000-2004
Editorial Board, Expert Opinion On Biological Therapy, 2001-current
Reviewer, Special Emphasis Panel Experimental Therapeutics I, NCI, NIH, 2001, 2003
Reviewer, GSF retreat – Wilbad Kreuth, Germany. Oct 2002
Member, Experimental Therapeutics II Study Section NCI, NIH 2002-2003
Scientific Advisory Board, Biological Development Association (Europe 2002-current)
Chair, Communications subcommittee, International Society for Biological Therapy, 2002-2005
Chair, Collaborations subcommittee, International Society for the Biological Therapy of Cancer (iSBTc), 2002-2005
Editorial Board, Journal of Immunotherapy 2003 - current
Member, Cancer Immunopathology and Immunotherapy Study Section NCI, NIH, 2003-2005
Ex-Officio Member, Leadership Cabinet, Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center 2003- current
Reviewer, Vienna Science and Technology Fund (WWTF Austrian non-profit agency), 2003
Consultant, Human applications laboratory, Norris Cancer Center, University of Southern California, 2003
Reviewer, NCI, NIH PO1 Site Visit, Baylor Institute for Immunology Research, 2004
Reviewer, International Agency for Research on Cancer, www.iarc.fr, 2004-2005
Scientific Advisory Board, Cell Genesys Inc., www.cellgenesys.com, South San Francisco, CA, 2004 – 2006
External Advisory Board, Center of Biomedical Research Excellence, University of Montana, Missoula, MT 2004 - 2009
Consultant, Vaccine Focus Panel, Cell Genesys Inc. South San Francisco, CA, 2006 – 2008
Board of Directors, NeoPharm, www.neophrm.com, Lake Forest, IL, 2004-2010
Consultant - External Advisory Committee, "Dendritic Cell Manipulation and Neoadjuvant Chemotherapy for Breast Cancer", (Program project – PO1) University of Nebraska Medical Center, Omaha, NE 2005
Chair, Program Committee, International Society for the Biological Therapy of Cancer (iSBTc), 2006-2008

Vice president / President elect, International Society for the Biological Therapy of Cancer (iSBTc), 2006-2008
Reviewer, Lab of Experimental Immunology, NCI, NIH, Fort Detrick, MD, June 12-14, 2006
Scientific Advisory Board, NeoPharm Inc. 2006-current
Ad Hoc Reviewer, TTT Study Section NCI, NIH, Oct. 9-10, 2006
Ad Hoc Reviewer, ONC-L Study Section NCI, NIH, Nov. 6, 2006
Consultant, Immunotherapy program, EMD Serono, Boston, MA, June 14, 2007
Consultant, Immunotherapy program, Pfizer, San Diego, CA, October 20, 2007
Consultant, Immunotherapy program, IDM, Phoenix, AZ, December 3, 2007
Member, iSBTc-FDA Taskforce on Immunotherapy Biomarkers Steering Committee, 2008-current
Member, iSBTc Clinical Endpoint and Response Criteria Working Group 2008 - current
External Board of Advisors, Yale SPORE in Skin Cancer Retreat, Yale University School of Medicine, New Haven, CT. March 28, 2008
Ad Hoc Reviewer, ONC-L Study Section NCI, NIH, June 16-17, 2008
Ad Hoc Reviewer, Clinical Center's Board of Scientific Counselors', NIH, September 8-9, 2008
President, Society for Immunotherapy of Cancer (SITC), previously the International Society for the Biological Therapy of Cancer (iSBTc), 2008-2010
Ad Hoc Reviewer, IMM-G M Special Emphasis Panel, NCI, NIH, Feb 17-18, 2009
External Scientific Advisory Board, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC. January 2009 – current
Advisory Panel for BiTe Antibody Therapeutics, Micromet Inc., March 2009-current
Ad Hoc Reviewer, Cell-Mediate Clinical Oncology Studies PO1 Special Emphasis Panel, NCI Clinical Studies, Rockville, MD, June 15-7-2009
Editorial Board, tumor immunology and biological cancer therapy section of the Journal of Translational Medicine. 2009 - present
Consultant, Novartis Institutes for Biomedical research, Cambridge, MA July 21, 2009
Chair, ZRG1 OTC-Y NCI, NIH, Special Emphasis Panel, August 26, 2009
Ad Hoc Reviewer, Developmental Therapeutics Study Section, September 24-25, 2009
Ad Hoc Reviewer, ZRG1 OTC W, NCI, NIH, Special Emphasis Panel, January 12, 2010
Member, NCI Clinical Studies PO1 Special Emphasis Panel, Bethesda, MD February 1-2, 2010
Chair, ZRG1 OTC-W 03 M, Cancer Therapeutics, NCI, NIH, Special Emphasis Panel, March 18, 2010
Editorial Academy, International Journal of Oncology, May 2010-current
Member, NCI Clinical Studies PO1 Special Emphasis Panel, Bethesda, MD June 16-18, 2010
Editorial Board, OncoImmunology, 2010 – current
External Advisory Board, Vaccine Branch, NCI, NIH, Bethesda, MD. 2011- current
Co-PI (with Dr. Walter Urba) for Providence Cancer Center site, NCI Cancer Immunotherapy Network (CITN), 2011 - current
Reviewer, Special Emphasis Panel Therapeutic Strategies for Cancer, NCI, NIH, Washington DC June 13-15, 2011
Reviewer, ZRG1 OTC-H CDT SBIR/STTR Sep Review Panel, NIH, July 14-15, 2011
Reviewer, ZRG1 OTC-H CDT SBIR/STTR Sep Review Panel, NIH, Washington DC, March 5-6, 2012
Co-PI (with Dr. Walter Urba) for Providence Cancer Center site, Bristol-Myers Squibb International Immuno-Oncology Network (II-ON), 2012 - current
Advisory Panel, Ventana, Roche: Westward Look Resort, Tucson, AZ, March 27-29, 2012

Scientific Advisory Board, McMasters Immunology Research Centre, Hamilton, Ontario, Canada 2012-current
Reviewer, ZRG1 OTC-H CDT SBIR/STTR Sep Review Panel, NIH, Washington DC, May 31st, 2012
Ad Hoc Reviewer, NIH Special Emphasis Panel - ZRG1 OTC-C(02) Telephone Review, September 9, 2012
Ad Hoc Reviewer, NIH Special Emphasis Panel - ZRG1 Telephone Review, October 3, 2012
Ad Hoc Reviewer, NIH Special Emphasis Panel - ZRG1 Telephone Review, November 6, 2012
Advisory Panel, Dendreon, Seattle, WA, December 11-12, 2012
Section Editor, Journal for Immunotherapy of Cancer (SITC Journal), 2012-current
Melanoma Advisory Board, Ventana/Roche, Tucson, AZ, March 11, 2013
Reviewer, NIH Director's Early Independence Award (ZRG1 BBBP-E 53 R), April 10, 2013
Ad Hoc Reviewer, NIH Special Emphasis Panel - ZRG1 Telephone Review, May 22, 2013
Advisory Panel, Dendreon, National Harbor, MD, November 10, 2013
Advisory Panel, Nodality, National Harbor, MD, November 10, 2013
Working Group, Melanoma Immunoscore, Ventana, Roche, Tucson, AZ February 24, 2014
Clinical Advisory Board, 3M, St Paul, MN, March 6, 2014
Advisor, Karmanos Cancer Institute, Wayne State University, Detroit, MI, 2014-2015
Consultant/Reviewer, Nodality, San Francisco, CA, Oct. 6, 2014.
Member, Council for Extramural Grants, American Cancer Society, 2014-2017
Scientific Advisory Board, Janssen/Johnson and Johnson, New York, NY, Dec. 1, 2014
Chair, Steering Committee, Global Colon Cancer Immunoscore Taskforce, SITC
Scientific Advisory Board, Health Sciences Division, PerkinElmer, Hopkinton, MA 2015- current
Scientific Advisory Board, AstraZeneca Pharmaceuticals LP, April 8, 2015
Scientific Advisory Board, Argos Therapeutics, Durham, NC, USA 2015 – current
Participant, China Cancer Immunotherapy Workshop of the China Center for Food and Drug International Exchange, Capital Hotel, Beijing, China, June 23, 2015
Scientific Advisory Board, Janssen/Johnson and Johnson, Hoboeken, NJ, Oct. 23, 2015
Scientific Advisory Board, PrimeVax Immuno-Oncology Inc, Garden Grove, CA 2015- current
Presenter and Panelist; EMA-CDDF Joint Meeting, at European Medicines Agency Headquarters, London, United Kingdom, February 4-5, 2016
Presenter and Panelist; Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer, At Institute of Medicine, Keck Building of The National Academies of Sciences, Engineering, and Medicine, Washington, DC 20001, February 29, 2016
Clinical and Scientific Advisory Board, Clearlight Diagnostics (Stanford), New Orleans, LA, April 17, 2016
Scientific Advisory Board meeting, Health Sciences Division, PerkinElmer, New Orleans, LA, April 18, 2016
Scientific Advisory Board, Kite Pharma, National Harbor, MD, November 9, 2016
Scientific Advisory Board, AstraZeneca Pharmaceuticals LP, Washington, DC, January 10, 2017
Scientific Advisory Board, Bayer's 1st Immuno-Oncology Roundtable, Washington, DC, April 2, 2017
FDA Policy Forum, Regulatory Science and Policy Tracks at the AACR Annual Meetings, presenter and panelist, http://webcast.aacr.org/console/player/35111?mediaType=audio& Washington DC, April 4, 2017
Scientific Advisory Board, Definiens/AstraZeneca Pharmaceuticals LP, Amsterdam, NL, April 24, 2017

Scientific Advisory Board, Celldex Therapeutics, Chicago, IL, June 5, 2017
Reviewer, Vaccine Branch, NCI, NIH, Scientific Retreat
Scientific Advisory Board, Argos, Conference call, July 13, 2017
Presenter and panelist at AACR-SITC Joint Congressional Briefing. Russell Senate Office Building, Capitol Hill, Washington DC, July 19, 2017 https://www.youtube.com/watch?v=y0UyxvJ2lrQ
Presenter and panelist at FDA-AACR: Oncology Dose Finding Workshop Part 3, Washington DC, July 20, 2017 https://www.fda.gov/Drugs/NewsEvents/ucm562746.htm http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/immuno-oncology-combination-therapies.aspx#.Wa2-GdMjHeR
Participant, Society for Immunotherapy of Cancer (SITC) Leadership Retreat with FDA, NCI and the Pharmaceutical Industry. Chicago, Il, August 6-8, 2017
Member and Reviewer, American Cancer Society Council Meeting, Atlanta, GA, Sept. 13-14, 2017
Guest participant, Society for Immunotherapy of Cancer (SITC) Board of Directors Meeting. National Harbor, MD, November 7, 2017
Scientific Advisory Board, Definiens/AstraZeneca Pharmaceuticals LP, NIH, Bethesda, MD, November 8, 2017 - Continuing
Chair, World Immunotherapy Council Leadership Meeting, National Harbor, MD. November 8, 2017
Member and Reviewer, American Cancer Society Council Meeting, Atlanta, GA, March. 15-16, 2018

**TEACHING ACTIVITIES**

Supervision of undergraduate student's thesis and medical student research rotations, Kalamazoo College and University of Michigan, 1990-1993
Graduate Faculty, Supervision, teaching and lecturing to MS, PhD, MD/PhD, and medical students of Oregon Health Sciences University and Oregon Graduate Institute, 1994-current
Supervised research rotations for Department of Surgery residents, Oregon Health Sciences University, 1996-1999
Supervised research rotations for Department of Surgery residents, Ludwig-Maximilians-Universitat, Munich, Germany, 1997-current
Organized and taught BMB 596, Immunotherapy and Gene therapy Strategies, Department of Molecular Biology and Biochemistry, Oregon Graduate Institute, Winter 1999, 2002
Supervision of Ph.D. students of The Vrije Universiteit Amsterdam, The Netherlands, 1999-2004
Co-Director (with Prof Yili Wang, Xi'an) Tumor Immunology Training Program, Joint program between the Earle A. Chiles Research Institute and Xi'an Jiaotong University, Xi'an, China. 2001-2010
Supervision of Ph.D. student of The University of Zurich, Zurich, Switzerland, 2012
Supervision of M.S. student of The Vrije Universiteit Amsterdam, The Netherlands, 2013

**MEMBERSHIPS AND OFFICES IN PROFESSIONAL SOCIETIES**

American Association of Immunologists
American Association of Cancer Research

Tumor Vaccine and Cell Therapy Working Group, Coordinator (1995-present)
International Society for the Biological Therapy of Cancer – Board of Directors (2002-2005)
International Society for the Biological Therapy of Cancer – Treasurer (2005-2006)
International Society for the Biological Therapy of Cancer – Vice-President (2006-2008)
Society for Immunotherapy of Cancer (previously, International Society for the Biological Therapy of Cancer) – President (2008-2010)
Society for Immunotherapy of Cancer–Chair, Executive Council (2010-2012)
Society for Immunotherapy of Cancer–Executive Council (2012-current)
World Immunotherapy Council (WIC) – Chair (2011 – current)

**EDITORIAL BOARDS**

Editorial Board, Current Molecular Medicine, 2000-current
Editorial Board, Cellular Immunology, 2000-current
Editorial Board, Expert Opinion On Biological Therapy, 2001-current
Editorial Board, Journal of Immunotherapy 2003 - current
Editorial Academy, International Journal of Oncology, May 2010-current
Editorial Board, Tumor Immunology and Biological Cancer Therapy Section of the Journal of Translational Medicine, 2009 - present
Editorial Board, OncoImmunology, 2010 - current
Section Editor, Journal for Immunotherapy of Cancer, 2012-2016

**CLINICAL TRIALS**

Principal Investigator: Adoptive Cellular Therapy of Renal Cell Cancer with Autologous Tumor Vaccine-Primed Anti-CD3-Activated Lymphocytes.
*FDA Investigational New Drug number IND-BB 5495*

Principal Investigator: Adoptive Cellular Therapy of Cancer Combining Direct HLA-B7/β2-microglobulin Gene Transfer with Autologous Tumor Inoculation for the Generation of Tumor-Primed Anti-CD3 Activated Lymphocytes
*NIH Recombinant DNA Activities Committee Approval June 6, 1995,*
*FDA Investigational New Drug number –IND-BB 6260*

Co- Investigator: Phase I trial using a CD80- modified Allogeneic Breast Cancer Cell Line To Vaccinate HLA-A2-Positive Women With Breast Cancer

Co-Investigator: Phase II Trial to Determine the Immune Response to a Mutated gp100 Melanoma Peptide (209-2M) Vaccine in HLA-A2.1+ Patients with a >1mm Melanoma on Initial Biopsy

Collaborator: Phase I/II study of a prime-boost schedule of human GM-CSF gene transduced irradiated prostate allogeneic cancer cell vaccines (Allogeneic prostate GVAX TM) in Hormone-naïve prostate cancer patients

Collaborator: Phase I/II study of a prime-boost schedule of human GM-CSF gene transduced irradiated prostate allogeneic cancer cell vaccines (Allogeneic prostate GVAX TM) in Hormone-refractory prostate cancer patients

Co-Investigator: Phase I/II study of GM-CSF Secreting Autologous Tumor Vaccines Engineered by Adenoviral-mediated Gene Transfer in Locally Advanced Non Small Cell Lung Cancer (NSCLC)"

Principal Investigator: Phase I/II Study of Human GM-CSF Gene-Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX™ ) in Advanced Prostate Cancer Patients made Lymphopenic by Chemotherapy and Infused with Autologous Peripheral Blood Mononuclear Cells. (02-200) (DOD funded DAMD 17-03-1-0097; and CD25-depletion; Kuni Foundation funded)

*FDA Investigational New Drug number –BB-IND 11716*

Co-Investigator: Phase I/II gp100 peptide immunization after lymphocyte depletion. (NCI funded clinical trial – P.I. Walter Urba)

Principal Investigator: Vaccination of Chemotherapy Induced Lymphopenic Unresectable stage III or stage IV Melanoma Patients following Reconstitution with Total or CD25-depleted PBMC (NCI funded clinical trial, Co-P.I. Walter Urba), *FDA Investigational New Drug number –BB-IND 13966*

Co-Investigator: A Pilot Study of Autologous Tumor DRibble Vaccine with Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer (NCI funded clinical trial – P.I. Walter Urba)

Co-Investigator: Randomized Phase II Trial of Cyclophosphamide with Allogeneic Non-small Cell Lung Cancer (NSCLC) Dribble Vaccine alone or with Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC. . (NCI SBIR R44 funded clinical trial – P.I. Walter Urba, Sponsor UbiVac) *FDA Investigational New Drug application – BB-IND 15377.*

Co-Investigator: A Pilot Study of DPV-001 DRibble Vaccine with Imiquimod in Advanced Prostate Cancer (Philanthropy funded trial – P.I. Brendan Curti, M.D., Sponsor, UbiVac). *FDA Investigational New Drug application – BB-IND 15377.*

Sponsor: Randomized Phase II Trial of Cyclophosphamide with Allogeneic Non-small Cell Lung Cancer (NSCLC) Dribble Vaccine alone or with Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC. . (NCI SBIR R44 funded clinical trial – P.I. Walter Urba, Sponsor UbiVac) *FDA Investigational New Drug application – BB-IND 15377.*

Sponsor: A Pilot Study of DPV-001 DRibble Vaccine with Imiquimod in Advanced Prostate Cancer (Philanthropy funded trial – P.I. Brendan Curti, M.D., Sponsor, UbiVac). *FDA Investigational New Drug application – BB-IND 15377.*

## GRANT SUPPORT

**Active**

| | | |
|---|---|---|
| 5 R01 CA142779-09 | Pardol (PI) | 01/31/19-01/30/20 |
| NIH | | Role: Co-Investigator |

**PD-1/PD-L1 modulation in cancer therapy - Subcontract**

The purpose of this collaboration is to test the hypothesis that biomarkers based on multiplexed IHC can be automated, standardized, and sufficiently reproducible to support immunotherapy clinical trials and eventually clinical testing. A positive result will be concordance across 6 participant sites for the full workflow including automated staining through to biomarker scores. De-identified patient tissue slides will be sent to Providence Portland Medical Center for analysis. The proposed workflow includes staining with TSA detection reagents using the Leica Bond Rx, imaging with multispectral microscope (Vectra Polaris, Perkin Elmer), and analyzing imagery with inForm software (Perkin Elmer).

**Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma**

The major goals are: 1) Phase I clinical trial to evaluate safety, pharmacokinetics, and estimate the

| | | |
|---|---|---|
| BMS II-ON | Urba/Fox (Co-PI) | 08/01/14-07/31/19 |
| **Sponsored Research Agreement** | | Role: C0-PI |

Development of multispectral Imaging to assess predictive biomarkers for immunotherapy

| | | |
|---|---|---|
| PerkinElmer | Fox (PI) | 02/01/17-12/31/19 |
| **Collaboration** | | Role: PI |

Evaluation/validation of Polaris Vectra as a platform for rapid multispectral evaluation of tumor biopsies.

Oncosec Fox (PI) 04/01/16-02/28/20
**Collaboration** Role: PI
Multispectral Imaging evaluation of intratumoral immunotherapy in patients with melanoma

Macrogenics Fox (PI) 02/01/2018-12/31/2019
**Collaboration**
Develop and perform multiplex IHC of patients receiving anti-CD123-anti-CD3 DART (Flotutuzumab)

**Completed**

993354956 Jensen (PI) 07/23/14-02/28/18
Janssen R&D Role: Co-Investigator
**Research Funding Agreement**
The major goals are: 1) Identify a dose of anti-VISTA that exhibits the greatest anti-tumor activity against established poorly immunogenic tumors and move that does to additional mechanistic studies; and 2) Characterize the mechanism(s) responsible for the anti-tumor effect of anti-VISTA alone, or fms inhibitor alone.

Viralytics Fox (PI) 01/01/15-11/30/18
Role: PI
**Sponsored Research Agreement**
The major goal of this project is to perform multispectral imaging of immune cell subsets and expression of PD-L1 on FFPE biopsy samples of melanoma from patients receiving Viralytic's Cavatac agent. Additional studies are aimed at characterizing expression of melanoma and viral antigens.

1 R21 CA190790-01 Curti (PI) 07/06/15-06/30/17
NIH Role: Co-Investigator
**Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma**
The major goals are: 1) Phase I clinical trial to evaluate safety, pharmacokinetics, and estimate the response rate of combination therapy with a galectin-3 inhibitor (GR-MD-02) plus ipilimumab in patients with metastatic melanoma and 2) Investigate the mechanisms by which combined therapy with GR-MD-02 and ipilimumab alleviates tumor-induced suppression and augments effector T cell activation and function.

993503425 Jensen (PI) 07/07/15-07/06/17
Janssen R&D Role: Co-Investigator
**Evaluate the impact of GVAX prime and Treg depletion on the effectiveness of listeria based vaccination**
The major goals of this project are: 1) To evaluate dose effects of LADD in the B16-D5 tumor model in the context of combination with adoptive T cell transfer; 2) To characterize the efficacy of LADD and GVAX (D5G6) prime boost combinations in the B16-G5 tumor model; and 3) To examine the phenotype and function of immune cells induced by gp100 LADD with and without GVAX.

5 R01 CA080964-14 Fox (PI) 04/01/99-02/29/16
NIH Role: PI
**Mechanisms that Regulate Tumor-Specific Immune Response**

The major goals of this project are: 1) To determine the requirements for efficient priming of therapeutic T cells in (RLM) hosts, compared to intact vaccinated animals; 2) To investigate the mechanisms responsible for the decreased efficiency/loss of priming to vaccination in lymphopenic hosts reconstituted with cells from (TBM) and develop strategies to overcome this inhibition; and 3) To characterize the nature and extent of CD4+ help required to maintain a therapeutic anti-tumor response following adoptive transfer-(specific-help).

2015 Research Support Grant Fox (PI) 01/01/15-12/31/15
OMSF Role: PI
**Development of "Immunoprofile" to direct therapy for OHNSCC**
The major goal of this project are: 1) Investigate with RNA-Seq the tumor-associated transcripts of resected stage III and IV tumors from a subset of 40 OHNSCC and 2) utilize multi-spectral imaging and objective assessment software to characterize 25 to 30 markers, identified in aim 1 as associated with progression, that are expressed by the tumor microenvironment of specimens in formalin fixed paraffin embedded (FFPE)
OHNSCC tumor samples from patients previously treated at our institution.

2010-011 Curti (PI) 04/01/10-03/31/16
Kuni Foundation
**Improvement of Prostate Cancer Vaccines by Elimination of Suppressor Cells**
The major goals are: 1) Study the toxicity and clinical effects of Cyclophosphamide, DRibble vaccine and Imiquimod in men with CRPC; 2) Characterize the number and function of Treg in the patients treated in Aim 1; and 3) Develop and use assays to study antigen specific immune responses to prostate cancer.

R44 CA121612-02A1 Hilton (PI) 09/01/09-12/31/16
NIH
**New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells**
The aims of our proposal are:1) Scale-up DRibble vaccine production, establish and validate SOPs, develop QA/QC procedures and lot-release criteria for DRibble vaccine. Continue efforts to develop a potency assays. 2) Conduct a randomized Phase II trial of docetaxel and DPV-1 combined with either GM-CSF or Imiquimod in stage IIIB and IV NSCLC patients. Determine vaccine safety and assess for evidence of objective clinical antitumor response. Milestones - Successful completion of the randomize Phase II Clinical trial and detection of objective clinical response in majority of patients. 3) Evaluation of possible biomarkers that may provide surogates of therapeutic effects and/or induction of an anti-tumor immune response. Milestones - Complete analysis of circulating tumor cell (CTC) numbers and antibody response pre and post docetaxel and DPV-1.

## BIBLIOGRAPHY

1. Dienst, SG, MacDonald, R, Toledo-Pereyra, LH, and **Fox, BA**: Modification of Donor Pretreatment Prolongs Canine Renal Allograft Survival. Transplantation Proc. 11(2):1465-1466, 1979.
2. Toledo-Pereyra, LH, **Fox, BA**, Gordon, DA, and Jennings, J: Lack of Blocking Effect of Chondroitin Sulfate on Lymphocyte Defined Antigens. Transplantation 27(6):429-430, 1979.

3. Gordon, DA, **Fox, BA**, and Toledo-Pereyra, LH: Cell Mediated Immune Response and Cimetidine. Michigan Academician 12(3):281-288, 1980.
4. **Fox, BA**, Westrick, PW, Oh, HK, and Dienst, SG: Effect of Immunosuppression of Murine Responses to Skin Allografts and Concanavalin A; Analysis of T Cell Subsets. Transplantation Proc. XV(3):1988-1992, 1983.
5. **Fox, BA**, Petty, HR: Characterization of a Monoclonal Antibody Defining a Macrophage Activation-Specific Cell Surface Antigen. Molecular Immunology 21(7): 681-4, 1984.
6. **Fox, BA,** Westrick, PW, and Nathanson, SD: Kinetics of the Mixed Lymphocyte Reaction Following Allogeneic Donor Specific Blood Transfusion in C57BL/6 Mice: Transplantation. 40(3):275-278, 1985.
7. Petty, HR, **Fox, BA**, Berg, KA, and Francis, JW: A Monoclonal Antibody (BMA-1) Reactive with Murine B Cells as Well as Resident and Elicited But Not Activated Macrophages. Immunology Letters 15:341-6, 1987.
8. **Fox, BA**, and Rosenberg, SA: Heterogeneous Lymphokine-Activated Killer Cell Precursor Populations; Development of a Monoclonal Antibody that Separates Two Populations of Precursors with Distinct Culture Requirements and Separate Target-Recognition Repertoires. Cancer Immunol. Immunother 29:155-166, 1989.
9. **Fox, BA**, Spiess, PJ, Kasid, A, Puri, RK, Mule, JJ, and Rosenberg, SA: In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor infiltrating lymphocytes. J. Biol. Resp. Mod. 9(5):499-511, 1990.
10. **Fox, BA**: New experimental approaches to the adoptive immunotherapy of cancer: Cytokines, gene therapy, oncogenes and transgenic mice. In: Basic and Clinical Research on Renal Cell Carcinoma. Eds. G. Staehler and S. Power. Springer-Verlag. Berlin, Heidelberg, New York. pg 165-188, 1992.
11. Nabel, GJ, Chang, AE, Nabel, EG, Plautz, GE, **Fox, BA**, Huang, L, and Shu, S. Immunotherapy of malignancy by in vivo gene transfer into tumors. Human Gene Therapy 3:399-410, 1992.
12. Wahl, WL , Plautz, GE, **Fox, BA**, Nabel, GJ, Shu, S, and Chang, AE: Generation of therapeutic lymphocytes after in vivo transfection of tumor with a gene encoding allogeneic class I MHC antigen. Surgical Forum 63:476-8, 1992.
13. Nabel, GJ, Nabel, E, Yang, Z, **Fox, BA**, Plautz, G, Gao-X, Huang, L, Shu, S, Gordon, D, and Chang, AE: Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. USA 90:11307-11 Dec. 1993.
14. Nabel, GJ, Chang, AE, Nabel, E, Plautz, G, Ensminger, W, **Fox, BA**, Felgner, P, Shu, S, and Cho, K,: Immunotherapy for cancer by direct gene transfer into tumors. Human Gene Therapy 5:57-77, 1994.
15. Nabel, GJ, **Fox, BA**, Post, L, Thompson, CB, Woffendin, C: A Molecular Genetic Intervention for AIDS - Effects of a Transdominant Negative Form of Rev. Human Gene Therapy 5: 79-92, 1994.
16. Shu, S, Krinock, RA, Matsumura, T, Sussman, JJ, **Fox, BA**, Chang, AE, and Terman, DS: Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells. J. Immunology 152(3):1277-88, 1994.
17. Poo, H, **Fox, BA**, and Petty, HR: Ligation of CD3 triggers transmembrane proximity between LFA-1 and corticalmicrofilaments in cytotoxic tumor infiltrating T cells: A quantitative resonance energy transfer microscopy study. J. Cellular Physiology 159(1):176-80, 1994.

18. Plautz, GE, Nabel, EG, **Fox, BA,** Yang, Z, Jaffe, M, Gordon, D, Chang, A, Nabel, GJ: Direct Gene Transfer for the understanding and treatment of human disease. Annals of the New York Academy of Sciences, New York, 716: 144-153 (May 31 1994).
19. Nabel, GJ, Nabel, E, Yang, Z, **Fox, BA**, Plautz, G, Gao-X, Huang, L, Shu, S, Gordon, D, and Chang, AE: Molecular Genetic Interventions for Cancer. CSHSQB LIX:699-707, 1994.
20. **Fox, BA**, Osterholzer, JJ, Mali, V, Schmogi, M: Trafficking and survival of effector T cells in vivo. in Immunotherapy of Cancer with Sensitized T Lymphocytes. ed. Chang, AE. and Shu, S. R.G. Landes Company, Austin. pg 91-109, 1994.
21. Wahl, WL, Strome, SE, Nabel, GJ, Plautz, GE, Cameron, MJ, San, H, **Fox, BA,** Shu, S, Chang, AE: Generation of Therapeutic T Lymphocytes after In Vivo Tumor Transfection with an Allogeneic Class I Major Histocompatibility Complex Gene. J. Immunotherapy 17:1-11, 1995.
22. **Fox, BA**, Woffendin, C, Yang, Z, San, H, Kumar, U, Gordon, D, Osterholzer, J, Nabel, GJ: Genetic Modification of Human Peripheral blood Lymphocytes with a Transdominant Negative Form of Rev: Safety and Toxicity. Human Gene Therapy 6:997-1004, 1995.
23. Hu, H-M, and **Fox, BA.** Transfer of Genes Encoding Antigens, Co-Stimulatory Molecules, or Adhesion/Accessory Molecules as a Strategy to Augment the Anti-Tumor Immune Response. Gene Therapy of Cancer. eds. Brenner, M.K. and Moen, R.C. Marcel Dekker Inc. New York, pg121-138, 1996.
24. **Fox, BA**, and Nabel, GJ: The potential role of gene transfer techniques in altering the immune response to tumors. In Immunotherapy and Cancer Vaccines. ed. Dalgleish, A.G., and Browning, M., Cambridge University Press, pg300-326, 1996.
25. Chang, AE, Aruga, A, Cameron, MJ, Sondak, VK, Normolle, DP, **Fox, BA**, Shu, S: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J. Clin. Oncology 15(2) 796-807, 1997.
26. **Fox, BA**, Drury, M, Hu, H-M, Huntzicker, EG, Cao, Z, Qie, W and Urba, WJ: Lipofection indirectly increases expression of endogenous MHC class I molecules on tumor cells. Cancer Gene Therapy 5(5):307-12, 1998.
27. Hu, H-M, Urba, WJ, and **Fox, BA**: Gene modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to type 1 cytokine profile. J. Immunology. 161:3033-3041, 1998.
28. Winter, H, **Fox, BA**: Adoptive Cellular Immunotherapy of Cancer. Current Opinion in Molecular Therapeutics. 1 (1):89-97, 1999.
29. Chu, Y, Hu, H-M, Winter, H Wood, WJ, Doran, T, Lashley, D, Bashey, J, Schuster, J, Wood, J, Lowe, B, Vetto, JT, Weinberg, AD, Puri, R, Smith, II JW, Urba, WJ, **Fox, BA**: Examining the immune response in sentinel lymph nodes of mice and men. Eur J Nucl Med, 26(4 Suppl):S50-3, Apr, 1999.
30. Winter, H, Hu, H-M, Urba, WJ, **Fox, BA**: Tumor regression after adoptive transfer of effector-T cells is independent of perforin or Fas-Ligand (APO-iL/CD95L). J. Immunology. 163:4462-4472, 1999.
31. Hu, H-M, Winter, H, Urba, WJ, and **Fox, BA**: Divergent Roles for $CD4^+$ Helper T Cells in the Priming and Effector Phases of Adoptive Immunotherapy. J. Immunology. 165: 4246-4253, 2000.
32. Winter, H, Hu, H-M, Urba, WJ, and **Fox, BA**: Immunotherapy of Melanoma: A Dichotomy Between the Requirement for IFN-γ in Vaccine Induced Antitumor Immunity, but not for Effective Adoptive Immunotherapy[1]. J. Immunology. 166:7370-7380, 2001.
33. Meijer, S.L., A.Dols, H-M.Hu, S.Jensen, C.H.Poehlein, Y.Chu, H.Winter, J.Yamada, T.Moudgil, W.J.Wood, T.Doran, L.Justice, B.Fisher, P.Wisner, R. Mehrotra, S. Rosenheim,

A.D.Weinberg, R.Bright, E.Walker, R.Puri, J.W.Smith II,W.J.Urba and **Fox, B.A;** Immunological and Molecular Analysis of the Sentinel Lymph Node: A Potential Approach to Predict Outcome, Tailor Therapy, and Optimize Parameters for Tumor Vaccine Development. J. Clin. Pharmacol. 41:81S-94S, 2001.

34. Meijer, S.L., Dols, A., Urba, W.J., Hu, H-M, Smith, J.W. II, Vetto, J., Wood, W., Doran, T., Chu, Y, Sayaharuban, P., Alvord, W.G., and **Fox, BA:** Adoptive cellular therapy with tumor vaccine draining draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J. Immunotherapy. 25(4):359-372, 2002.
35. Hu, HM, Winter, H, Ma, J, Croft, M, Urba, WJ, **Fox, BA**: CD28, TNF Receptor, and IL-12 Are Critical for CD4-Independent Cross-Priming of Therapeutic Antiumor $CD8^+$ T Cells. J. Immunology 169:4897-4904, 2002.
36. Hu, HM, Poehlein, CH, Urba, WJ, and **Fox BA**: Development of Antitumor Immune Responses in Reconstituted Lymphopenic hosts. Cancer Research 62, 3914-3919, Jul 2002.
37. Poehlein, CH, Hu, HM, Yamada, J, Assmann, I, Alvord, WG, Urba, WJ, **Fox, BA**: TNF Plays an Essential Role in Tumor Regression after Adoptive Transfer of Perforin/IFN-γ Double Knockout Effector T Cells. J. Immunology. 170:2004-2013, 2003.
38. Jensen, SM, Meijer, SL, Kurt, RA, Urba, WJ, Hu, HM, **Fox, BA**: Regression of a Mammary Adenocarcinoma in $STAT6^{-/-}$ Is Dependent on the Presence of STAT6-Reactive T Cells. J. Immunology. 170:2014-2021, 2003.
39. Dols, A, Meijer, Hu, HM, Goodell, V, Disis, ML, von Mensdorff-Pouilly, S, Verheijen, R, Alvord, WG, Smith II, JW, Urba, WJ, **Fox, BA**: Identification of Tumor-Specific Antibodies in Patients with Breast Cancer Vaccinated with Gene-Modified Allogeneic Tumor Cells. J. Immunotherapy 26(2):163-170, 2003.
40. Winter, H, Hu, H-M, Poehlein, CH, Huntzicker, E, Osterholzer, JJ, Bashy, J, Lashley, D, Lowe, B, Yamada, J, Alvord, G, Urba, WJ and **Fox, BA:** Tumor-Induced Polarization of Tumor Vaccine-Draining Lymph Node T Cells to a Type 1 Cytokine Profile Predicts Inherent Strong Immunogenicity of the Tumor and Correlates with Therapeutic Efficacy in Adoptive Transfer Studies. Immunology 108(3): 409-19, 2003.
41. Smith J.W.II, Walker EB, **Fox BA**, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ. Modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. Apr 15:21(8):1562-73, 2003.
42. Dols, A, Meijer, SL, Smith II, WJ, **Fox, BA**, Urba, WJ: Allogeneic breast cancer cell vaccines. Clin Breast Cancer 3 Suppl 4: S173-80, 2003.
43. Ruettinger, D, Li, R, Urba, WJ, **Fox, BA**, and Hu, H-M: Evaluation of a preclinical model of bone metastases for Immunotherapy. Eur. Surg. Res. Jul-Aug;35(4):346-51. 2003.
44. Ma, J, Urba, WJ, Si, L,Wang, Y, **Fox BA**, Hu, H-M: Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur. J. Immunol. 33(8):2123-32, 2003.
45. Dols, A, Smith II, JW, Meijer, SL, **Fox, BA,** Hu, H-M, Walker, E, Rosenheim, S, Moudgil, T, Doran, T, Wood, W, Seligman, M, Alvord, G, Schoof, D, Urba, WJ: Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified HLA-A2-matched, allogeneic, breast cancer cell line: Clinical and immunological results. Human Gene Therapy, 14 (11):1117-23 2003.
46. Hu, H-M, Dols, A, Meijer, SL, Floyd, K, Walker, E, Urba, WJ, **Fox, BA:**"Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes." J. Immunotherapy **27**(1):48-59 2004.

47. Li R, Ruttinger D, Urba WJ, **Fox BA**, and Hu H-M: Targeting and Amplification of Tumor Immune Killing Mechanisms by Pro-Smac I. International J. of Cancer. 109(1):85-94 2004.
48. Nemunaitisl, J, Sterman, D, Jablons, D, Smith II, JW, **Fox, B**, Maples, P, Hamilton, S, Borellini, F, Lin, A, Morali, S, Hege, K: Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines (GVAX) in Non-Small Cell Lung Cancer. J. Natl Cancer Inst. 96(4):326-31, 2004.
49. Walker, EB, Haley, D, Miller, W, Floyd, K, Wisner, KP, Sanjuan, N, Maecker, H, Romero, P, Hu, HM, Alvord, WG, Smith, JW II, **Fox, BA**, Urba, WJ: gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells." Clin Cancer Res **10**(2): 668-80, 2004.
50. Meijer, SL, Dols, A, Hu, HM, Chu, Y, Moudgil, T, Wood, Vetto, JT, Smith II, JW, Urba, WJ, and **Fox, BA**: Reduced L-selectin ($CD62L^{Low}$) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine: Cellular Immunol. 227 : 93-102, 2004.
51. F Hinds MT, Courtman DW, Goodell T, Kwong M, Brant-Zawadzki H, Burke A, **Fox BA,** Gregory KW. Biocompatibility of a xenogenic elastin-based biomaterial in a murine implantation model: the role of aluminum chloride pretreatment. J Biomed Mater Res 69A(1):55-64. 2004
52. Ma. J, Poehlein, C.H., Jensen, S., LaCelle, M.G ., Moudgil, T.M., Rüttinger, D., Haley, D, Goldstein, M ., Smith III, J.W.. Curti, B, Ross, H., Walker, E., Hu, H-M., Urba, W.J., **Fox, B.A**. Manipulating the Host Response to Autologous Tumor Vaccines. Dev. Biol. Basel 116: 93-107, 2004
53. Rüttinger D, Li R, Urba WJ, **Fox BA,** Hu HM: Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells. Clin Exp Metastasis. 2004;21(4):305-12. PMID: 15554386
54. **Fox, BA**. Review of - Melanoma vaccines: what we know so far. Oncology 19(1):112-5. 2005
55. Friedman, K.M. and **Fox, B.A.** The promising future of proteomics in cancer diagnosis and treatment. Eur. J. Gastro and Hep. 17:701-703. 2005.
56. Poehlein, CH, Ruttinger, D, Ma, J, Hu, H-M, Urba, WJ, **Fox, BA**: Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep. 7(5) 383-92, 2005.
57. Wang, LX, LI, R, Yang, G, Lim, M, O'Hara, A, Chu, Y, Restifo, NP, **Fox, BA**, Urba, WJ, and Hu, HM: IL-7 dependent expansion and persistence of adoptively transferred T cells in lymphodepleted mice after vaccination leads to tumor regression and editing. Cancer Research. 65:10569-77, 2005. *PMCID: PMC2241747.*
58. Ma, J, Wang, YL, Hu, HM, **Fox, BA**, Si, LS: Mechanism of augmented anti-tumor immunity in reconstitute lypmphopenice mice immunized with melanoma vaccine. Zhonghua Zhong Liu Za Zhi. 27(12) 708-12, 2005.
59. Nemunaitis, J, Jahan, T, Ross, H, Sterman, D, Richards, D, **Fox, B**, Jablons, D. Aimi, J, Lin, A, and Hege, K: Phase 1/2 trail of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Therapy. 13(6):555-562, 2006.
60. van den Engel NK, Winter H, Ruttinger D, Shau I, Schiller M, Mayer B, Moudgil T, Meimarakis G, Stolte M, Jauch KW, **Fox BA**, Hatz RA: Characterization of immune responses in gastric cancer patients: A possible impact of H. pylori to polarize a tumor-specific type 1 response? Clin Immunol. Epub 120(3): 285-96. 2006.

61. Ruttinger D, Winter H, van den Engel NK, Hatz RA, Schlemmer M, Pohla H, Grutzner S, Schendel DJ, **Fox BA**, Jauch KW: Immunotherapy of lung cancer: an update. Onkologie 2006, 29(1-2):33-38.
62. He, H, Wisner, P, Yang G, Hu, HM, Haley, D, Miller, W, O'Hara, A, Alvord, WG, Clegg CH, **Fox, BA**, Urba, WJ, Walker, EB: Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med 4(1):24. 2006. *PMCID: PMC1502139.*
63. Winter, H, van den Engel, NK, Poehlein, CH, Hatz, RA, **Fox, BA**, Hu, HM: Tumor-specific T cells signal tumor destruction via the lymphotoxin β receptor. J Transl Med 5:14. 2007. *PMCID: PMC1838896.*
64. Carson WE, Allen A, Weiner LM, Cheever, MA, **Fox, BA**, Keilholz U, Wigginton JM, Sondel PM, Atkins MB, Hwu P: Immunotherapy comes of age: overview of the 21(st) Annual Meeting and associated programs of the International Society for Biological Therapy of Cancer Los Angeles, CA, USA, 27 - 29 October 2006. Expert Opin Biol Ther. Mar;7(3):419-422. 2007.
65. Sakamoto, N, Tsuji, K, Muul, LM, Lawler, AM., Petricioin, EF, Candotti, F, Metcalf, JA, Tavel, JA, Lane, HC, Urba, WJ, **Fox, BA**, Varki, A, Lunney, JK, Rosenberg, AS. Bovine apolipoprotein B-100 is a dominant immunogen in the therapeutic cell populations cultured in FCS in mice and humans. Blood Mar 29. 2007. *PMCID: PMC1924480*
66. Meijer, SL, Dols, A, Jensen, SM, Hu, H-M, Miller, W, Walker, EB, Romero, Pedro, **Fox, BA**, and Urba, WJ. Induction of Circulating Tumor-reactive $CD8^+$ T Cells After Vaccination of Melanoma Patients with the $gp100_{109\text{-}2M}$ Peptide. J Immunother 30:533-543. 2007.
67. Rüttinger, D, Hatz, RA, Jauch, KW, **Fox, BA**: Current Immunotherapeutic Strategies in Lung Cancer. Surg Oncol Clin N Am. 16(4): 901-18. 2007.
68. Ruttinger, D, van den Engel, NK, Winter, H, Schlemmer, M, Pohla, H, Grutzner, S, Wagner, B, Schendel, DJ, **Fox, BA**, Jauch, KW, Hatz, RA. Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response. J Transl Med 5:43. 2007. *PMCID: PMC2020458*
69. Winter, H, van den Engel, NK, Ruttinger, D, Schmidt, J, Schiller, M, Poehlein, CH, Lohe, F, **Fox, BA**, Jauch, KW, Hatz, RA, Hu, HM: Therapeutic T cells induce tumor-directed chemotaxis of innate immune cells through tumor-specific secretion of chemokines and stimulation of B16BL6 melanoma to secrete chemokines. J Transl Med. 5:56. 2007. *PMCID: PMC2203985*
70. Ruttinger D, Rui, L, Poehlein, CH, Haley, D, Walker, EB, Hu, HM, **Fox, BA**: Increased susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-Smac fusion protein. J Immunotherapy. 31(1):43-51. 2008.
71. Walker EB, Haley D, Petrausch U, Floyd K, Miller WL, Sanjuan N, Alvord G, **Fox BA**, Urba WJ: Phenotype and Functional Characterization of Long-Term gp100-Specific Memory $CD8^+$ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization. J Clin Can Res. 14(16):5270-83. 2008. *PMCID: PMC2756994.*
72. Butterfield LH, Disis ML, **Fox BA**, Lee PP, Khleif S, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen T, Kirkwood J, Macalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff Jr CL, Stroncek DF, Streicher H, Xu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM: A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on Immunotherapy Biomarkers". J Trans Med. 6:81. 2008. *PMCID: PMC2630944.*

73. Li, Y, Wang, LX, Pang, P, Twitty, C, **Fox, BA**, Aung, S, Urba, WJ, Hu, HM: Cross-presentation of tumor associated antigens through tumor-derived authophagosomes. Autophagy. 5:1-2. 2009. *PMCID:PMC3128909.*
74. Tahara H, Sato M, Thurin M, Wang E, Butterfield L, Disis ML, Fox BA, Lee PP, Khleif S, Wigginton JM, Ambs S, Akutsu Y, Chaussabel D, Doki Y, Eremin O, Fridman, WH, Hirohashi Y, Imai K, Jacobson J, Jinushi M, Kanamoto A, Kashani-Sabet M, Kato K, Kawakami Y, Kirkwood JM, Kleen To, Lehmann PV, Liotta L, Lotze MT, Maio M: Emerging concepts in biomarker discovery; The US-Japan workshop on immunological molecular markers in oncology. J Trans Med 7:45 2009. *PMCID: PMC2724494*
75. Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB, Akporiaye E, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, **Fox BA**: Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med. (6):673-82, Aug;9 2009. *In PMCID: PMC3110749*
76. Petrausch, U, Jensen, SM, Twitty, C, Poehlein, CH, Haley, DP, Walker, EB, **Fox, BA**: Disruption of TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T Cells and Facilitates Therapeutic Antitumor Immunity. J Immunol, 183:3682 -3689, 2009. *PMCID: PMC2850273*
77. Romero, P, Fox, **BA**: Announcing the tumor immunology and biological cancer therapy section (edited by iSBTc) of the Journal of Translational Medicine. 7:80, 2009. *PMCID: PMC2753320*
78. Poehlein, CH, Haley, D, Walker, EB, Fox, **BA**: Depletion of tumor-induced regulatory T cells prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in lymphopenic hosts. Eur J Immunology 39:3121-3133, 2009. *PMCID: PMC2850261*
79. LaCelle, MG, Jensen, SM., and **Fox, BA**.: Partial CD4 Depletion Reduces Regulatory T cells Induced by Multiple Vaccinations and Restores Therapeutic Efficacy. Clinical Cancer Research. Nov 15;15(22):6881-90. Epub 2009. *PMCID: PMC2784281.*
80. Rüttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, **FoxBA**, Weber JS. Immunotherapy of Cancer: Key findings and Commentary on the Third Tegernsee conference. Oncologist Jan 8 2010 *PMCID:PMC3227889*
81. Hales RK, Banchereau J, Ribas A, Tarhini AA, Weber JS, **Fox BA,** Drake CG. Assessing oncologic benefit in clinical trials of immunotherapy agents. Ann Oncol. Mar 17 2010. [Epub ahead of print] *PMID: 20237004*
82. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, **Fox BA**, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother. 33(4):335-51 May 2010. *PMCID: PMC2941912*
83. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, Urba WJ, Weinberg AD, Curti B, **Fox BA.** Signaling Through OX40 Enhances Antitumor Immunity. Semin Oncol. 2010. Oct;37(5):524-32. *PMCID:PMC2997672*
84. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, **Fox BA**, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM: Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6$^{th}$-7$^{th}$ 2010". J. Transl Med. 2011 Mar 26;9:32. *PMCID:PMC3078100*

85. Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, Pawelec G, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL, Wigginton JM, Marincola F, Khleif S, **Fox BA**, Disis ML.: Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res. 2011. May 15:17(10):3064-3076. *PMCID: PMC3096674*
86. Winter H, van den Engel NK, Rusan M, Schupp N, Poehlein CH, Hu HM, Hatz RA, Urba Wj, Jauch KW, **Fox BA**, Rüttinger D: Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis. 2011. Jun;3(2):105-14. *PMCID: PMC3256502*
87. Church SE, Jensen SM, Twitty CG, Bahjat K, Hu HM, Urba WJ, **Fox BA**: Multiple Vaccinations: Friend or Foe. Cancer J. 2011 Sep;17(5):379-96. *PMCID: PMC3614402*
88. Bedognetti D, Balwit JM, Wang E, Disis ML, Britten CM, Delogu LG, Tomei S, **Fox BA**, Gajewski TF, Marincola FM, Butterfield LH: SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools-a company in the land of biomarker discovery. J Transl Med. 2011 Sep 19;9:155. *PMCID: PMC3189883*
89. Twitty C, Jensen SM, Hu HM, **Fox, BA**: Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses Against Short-Lived Proteins Through a P62-Dependent Mechanism. Clin Cancer Res. 2011 Oct 15:17(20):6467-81. *PMCID:PMC3298078*
90. Li, Y, Wang, LX, Pang, P, **Fox BA,** Urba WJ and Hu H-M: Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy Clin Can Res, 2011 Nov15:1;7(22):7047-57 *PMCID:PMC3495614*
91. **Fox BA**, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML: Defining the Critical Hurdles in Cancer Immunotherapy. J Transl Med. 2011 Dec 14;9(1):214. *PMCID: PMC3338100*
92. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, **Fox BA**, Gajewski TF, Ascierto PA: The Immune Score as a New Possible Approach for the Classification of Cancer. J Transl Med. 2012 Jan 3;10(1):1. *PMCID: PMC3269368*
93. Phelps L, **Fox BA**, Marincola FM: Supporting the advancement of science: Open access publishing and the role of mandates. J Transl Med. 2012 Jan 10:13. *PMCID: PMC3269380*
94. Montesarchio V, Grimaldi AM, Box BA, Rea A, Marincola FM, Ascierto PA: Lean Oncology: A new model for Oncologists. J Transl Med. 2012 Apr 25:10(1):74 [Epub ahead of print]. PMID:22533796
95. Schuberth PC, Jakka G, Jensen SM, Wadle A, Gautschi F, Haley D, Haile S, Mischo A, Held G, Thiel M, Tinguely M, Bifulco CB, **Fox BA**, Renner C, Petrausch U: Effector memory and central

memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013 Apr;20(4):386-95.: 10.1039/gt2012.48 [Epub ahead of print] *PMID:22739387*

96. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, **Fox BA**, Gajewski TF, Gershenwalk JE, Gogas H, Grossmannn K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Steward R, Wang E, Mozzillo N, Marincola F: Future Persepctives in Melanoma Research. Meeting report from the "Melanoma Research: a bridge from Napels to the World. J Transl Med 2012 Jul 10.83. *PMCID: PMC3390271*
97. Jensen, S.M., Twitty, C.G., Maston, L.D., Antony, P.A., Lim, M., Hu, H-M., Petrausch, U., Restifo, N.P., and **B.A. Fox.** Increased Frequency of Suppressive Regulatory T Cells and T-cell Mediated Antigen Loss Results in Murine Melanoma Recurrence. J Immuno 2012 *Jul 15;189(2):767-76. PMCID: PMC3552612*
98. Yi Y, Zhou Z, ShuS, Fang Y, Twitty C, Hilton TL, Aung S, Urba WJ, **Fox BA**, HU HM, Li Y: Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. 2012 Sept Oncolmmunology 1:6, 1-3. *PMCID: PMC3489765*
99. Galon J, Pagès F, Marincola FM, Thurin M, Lugli A, Zlobec I, Bifulco C, Botti G, Tatangelo F, Britten CM, Chouchane L, DelRio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Angell H, Vidal-Vanaclocha F, Allison J, Gnjatic S, Hakansson L, Huber C, Singh H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke B, Wouters B, Wang E, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Kreiter S, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope F, Trinchieri G, Gajewski TF, Ascierto PA, **Fox BA** : Cancer classification using the Immunoscore: A worldwide task force, J Transl Med, 2012, Oct 3 10:205. *PMCID: PMC3554496*
100. Ascierto, PA, Capone M, Urba WJ, Bifilco CB, Botti G, Lugli A, Marincola FM, Ciliberto G, Galon J, **Fox BA**, The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med, 2013 Mar 11(1):54. PMCID: *PMID:23452415*
101. Church SE, Jensen SM, Antony PA, Restifo NP, and **Fox BA**: Tumor-specific $CD4^+$ T cells maintain effector and memory tumor-specific $CD8^+$ T cells. European J. Immunol. 2014 Jan; 44(1):69-79. Sep 30 2013 [Epub ahead of print]. *PMID: 24114780. PMCID: PMC4283993*
102. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, **Fox BA**, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M: Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge", Napoli, December 2nd-4th, 2012. J Transl Med. 2013 Jun 3 11(1):137. *PMID:23731854 PMCID: PMC3681569*
103. Sunay M, Marincola F, Khleif SN, Silverstein SC, **Fox BA,** Galon J, Emens LA. Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012 *Journal for ImmunoTherapy of Cancer.* 2013, **1**:9 (27 June 2013)
104. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker E, Chisholm L, Floyd K, Walker J, Gonzalez I, Meeuwsen T, **Fox BA**, Moudgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L, Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD: OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients: Cancer Res. 2013 Oct 31. PMID: 24177180

105. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, **Fox BA**, Pagès F: Towards the introduction of the Immunoscore in the classification of malignant tumors. J Pathol. 2014 Jan;232(2):199-209. *PMCID: PMC3681569*
106. Graff JN, Puri S, Bifulco C, **Fox BA**, Beer TM. Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. Cancer Immunology Research *Published OnlineFirst February 3, 2014; doi:10.1158/2326-6066.CIR-13-0193*
107. Wei Ye, Yun Xing, Christopher Paustian, Rieneke van de Ven, Tarsem Moudgil, Traci L. Hilton, **Bernard A. Fox**, Walter J. Urba, Wei Zhao, Hong-Ming Hu. Cross-Presentation of Viral antigens in DRibbles Leads to Efficient Activation of Virus-Specific Human Memory T cells. J Transl. Med. *2014 April 16;12:100 PMID: 24735498*
108. Winter, H., **Fox, BA**, Ruettinger, D. Future of Cancer Vaccines. Methods Mol. Biol. 2014;1139:555-64
109. Butterfield LH, Disis ML, **Fox BA**, Khleif SN, Marincola FM. Preamble to the 2015 SITC immunotherapy biomarkers taskforce. J Immunother Cancer. 2015 Mar 24;3:8. doi: 10.1186/s40425-015-0052-6. eCollection 2015. PMID: 25806107
110. Lavotshkin S, Jalas JR, Torisu-Itakura H, Ozao-Choy J, Lee JH, Sim MS, Stojadinovic A, Wainberg Z, Bifulco CB, **Fox BA**, Bilchik AJ. Immunoprofiling for Prognostic Assessment of Colon Cancer: a Novel Complement to Ultrastaging. J Gastrointest Surg. 2015 Mar 26. [Epub ahead of print]
111. Curran MA, **Fox BA**, Redmond WL. Editorial: Advances in Combination Tumor Immunotherapy. Front Oncol. 2015 Sep 22;5:198. doi: 10.3389/fonc.2015.00198. PMID: 26442210
112. Zipei Feng [1,2]*, Sachin Puri[1]*, Tarsem Moudgil[1], William Wood[1], Clifford C. Hoyt[3], Chichung Wang[3], Walter J. Urba[1], Brendan D. Curti[1], Carlo B. Bifulco[1,4] and **Bernard A. Fox**[1,5]. Multispectral Imaging of Formalin-Fixed Tissue Predicts Ability to Generate Tumor-infiltrating lymphocytes from Melanoma. Journal for Immunotherapy of Cancer, 2015 **3**:47 doi:10.1186/s40425-015-0091-z PMID: 26500776 PMCID: PMC4617712
113. Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, **Fox BA**. Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. J Oral Maxillofac Surg. 2015 Dec;73(12 Suppl):S107-15. doi: 10.1016/j.joms.2015.05.026. PMID:26608138
114. Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, **Fox BA**, Weinberg AD, Urba WJ. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. PMID:26614363
115. Yuan J, Wang E, **Fox BA**. Immune Monitoring Technology Primer: protein microarray ('seromics'). J Immunother Cancer. 2016 Jan 19;4:2. doi: 10.1186/s40425-016-0106-4. PMID:26788323 PMCID: PMC4717548
116. Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y,

Zwierzina H, Butterfield LH, **Fox BA**. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. PMID:26788324

117. Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, Gough MJ, **Fox BA**, Weinberg AD, Urba WJ. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment Oral Oncol. 2016 Jan;52:1-10. doi: 10.1016/j.oraloncology.2015.11.009. Epub 2015 Nov 21. Review.
118. Kohrt HE[1], Kohrt HE[1], Tumeh PC[2], Benson D[3], Bhardwaj N[4], Brody J[5], Formenti S[6], **Fox BA**[7], Galon J[8], June CH[9], Kalos M[10], Kirsch I[11], Kleen T[12], Kroemer G[13], Lanier L[14], Levy R[15], Lyerly HK[16], Maecker H[17], Marabelle A[18], Melenhorst J[19], Miller J[20], Melero I[21], Odunsi K[22], Palucka K[23], Peoples G[24], Ribas A[25], Robins H[26], Robinson W[27], Serafini T[28], Sondel P[29], Vivier E[30], Weber J[31], Wolchok J[32], Zitvogel L[33], Disis ML[34], Cheever MA[35]; Cancer Immunotherapy Trials Network (CITN). Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J. ImmunoTher Cancer. 2016 Mar 15;4:15. doi: 10.1186/s40425-016-0118-0. eCollection 2016.
119. Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, **Fox BA**, Cheng AC, Bui TG, Tucker C, Hoen H, Weinberg A. OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer. Clin Transl Immunology. 2016 Apr 15;5(4):e70. doi: 10.1038/cti.2016.16. eCollection 2016 Apr.PMID: 27195113 PMCID: PMC4855266
120. Feng Z, Jensen SM, Farhad M, Neuberger M, Bifulco CB, and **Fox BA**. Multispectral Imaging of T and B cells in Murine Spleen. J Immunol. 2016 May 1;196(9):3943-50. PMID: 26994219 –Journal of Immunology Cover / May 1st 2016. PMCID: PMC4834492
121. Page DB, Hulett TW, Hilton TL, Hu HM, Urba WJ, **Fox BA.** Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine. J Immunother Cancer. 2016 May 17;4:25. doi: 10.1186/s40425-016-0130-4. eCollection 2016. Review. PMID: 27190627 PMCID: PMC4869314
122. Galon J, **Fox BA**, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, Capone M. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016 Sep 20;14:273. doi: 10.1186/s12967-016-1029-z. PMID: 27650038
123. Bell RB, Gough MJ, Seung SK, Jutric Z, Weinberg AD, **Fox BA**, Crittenden MR, Leidner RS, Curti B. Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. Oral Oncol. 2016 Oct;61:166-76. Doi 10.1016/j.oraloncology. 2016.08.020. Epub 2016 Sep 7. PMID: 27614589
124. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, **Fox BA**, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 Nov 15;14(1):313.
125. Yu G.,* , Li Y.,* , Cui Z., Morris N.P., Weinberg A.D., **Fox B.A.**, Urba, W.J., Wang L., & Hu H-M. Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. Scientific Reports | 6:37558 | DOI: 10.1038/srep37558
126. Ng SS, Nagy BA, Jensen SM, Hu X, Alicea C, **Fox BA**, Felber BK, Bergamaschi C, Pavlakis GN. Heterodimeric IL-15 treatment enhances tumor infiltration, persistence and effector

functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion. Clin Cancer Res. 2016 Dec 16.1808.2016. [Epub ahead of print] PMID: 27986749

127. Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, **Fox BA**, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1.
128. Bethmann D, Feng Z, **Fox BA**. Immunoprofiling as a predictor of patient's response to cancer therapy-promises and challenges. Curr Opin Immunol. 2017 Apr;45:60-72. doi: 10.1016/j.coi.2017.01.005. Epub 2017 Feb
129. Yu G[1], Moudgil T, Cui Z, Mou Y, Wang L, **Fox BA,** Hu HM. Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation. J Immunother. 2017 Mar 31.
130. Gulley JL, Berzofsky JA, Butler MO, Cesano A, **Fox BA**, Gnjatic S, Janetzki S, Kalavar S, Karanikas V, Khleif SN, Kirsch I, Lee PP, Maccalli C, Maecker H, Schlom J, Seliger B, Siebert J, Stroncek DF, Thurin M, Yuan J, Butterfield LH. Immunotherapy biomarkers 2016: Overcoming the barriers. *J Immunother Cancer*. 2017 Mar 21;5(1):29.
131. Feng Z, Daniel Bethmann[1,3#], Matthias Kappler[4#], Carmen Ballesteros-Merino[1], Alexander Eckert[4], R. Bryan Bell[1,5], Allen Cheng[5], Tuan Bui[5], Rom Leidner[1,5], Walter J. Urba[1], Kent Johnson[6], Clifford Hoyt[6], Carlo B. Bifulco[1,7], Juergen Bukur[8], Claudia Wickenhauser[3#], Barbara Seliger[8#] and **Bernard A.Fox[1,9#]** Multi-parametric immune profiling in HPV-negative oral squamous cell cancer. *JCI Insight.* 2017;2(14):e93652. doi:10.1172/jci.insight.93652. PMID: 28724788
132. Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, **Fox BA**. Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. *Clin Cancer Res*. 2017 Aug 28. doi: 10.1158/1078-0432.. [Epub ahead of print] PMID: 28855348
133. Masucci GV, Cesano A, Eggermont A, **Fox BA**, Wang E, Marincola FM, Ciliberto G, Dobbin K, Puzanov I, Taube J, Wargo J, Butterfield LH, Villabona L, Thurin M, Postow MA, Sondel PM, Demaria S, Agarwala S, Ascierto PA. The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. *J Transl Med*. 2017 Nov 3;15(1):223. doi: 10.1186/s12967-017-1325-2. PMID: 29100546
134. Baird JR, Feng Z, Xiao HD, Friedman D, Cottam B, **Fox BA**, Kramer G, Leidner RS, Bell RB, Young KH, Crittenden MR, Gough MJ. STING expression and response to treatment with STING ligands in premalignant and malignant disease. *PLoS One*. 2017 Nov 14;12(11):e0187532. doi: 10.1371/journal.pone.0187532. eCollection 2017. PMID: 29135982
135. Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, **Fox BA**, & Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. *OncoImmunology* [Epub ahead of print], Nov 17, 2017
136. Bell RB, **Fox BA**. Relationships matter in oral cancer: will single-stain immunohistochemistry become irrelevant in the age of multispectral imaging? Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Dec;124(6):517-518. doi: 10.1016/j.oooo.2017.09.010. Epub 2017 Sep 28. PMID: 29169510
137. Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C, Neuberger M, Walker E, Hu HM, Urba WJ, **Fox BA**. A pilot study of an

autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. J Immunother Cancer. 2017 Dec 19;5(1):103. doi: 10.1186/s40425-017-0306-6. PMID: 29258618

138. Rozanov DV, Rozanov ND, Chiotti KE, Reddy A, Wilmarth PA, David LL, Cha SW, Woo S, Pevzner P, Bafna V, Burrows GG, Rantala JK, Levin T, Anur P, Johnson-Camacho K, Tabatabaei S, Munson DJ, Bruno TC, Slansky JE, Kappler JW, Hirano N, Boegel S, **Fox BA**, Egelston C, Simons DL, Jimenez G, Lee PP, Gray JW, Spellman PT. MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J. Proteomics 2018 Jan 10; 176:13-23. PMID: 29331515
139. Tyler W. Hulett[1,4], Shawn M. Jensen[1], Larry L. David[2,3], Ashok P. Reddy[2,3], Phillip A. Wilmarth[2,3], Carmen Ballesteros-Merino[1], Michael E. Afentoulis[1], Christopher Dubay[1], and **Bernard A. Fox**[1,4*] Coordinated responses to individual tumor antigens by IgG antibody and CD8+ T cells following cancer vaccination. J. ImmunoTher Cancer 2018 Apr 5;6(1):27 PMID: 29618380
140. Franck Pagès[1,2,3,4], Bernhard Mlecnik[1,2,3], Florence Marliot[1,2,3,4], Gabriela Bindea[1,2,3], Fang-Shu Ou[5], Carlo Bifulco[6], Alessandro Lugli[7], Inti Zlobec[7], Tilman T. Rau[7], Martin D. Berger[8], Iris D. Nagtegaal[9], Elisa Vink-Borger[9], Arndt Hartmann[10], Carol Geppert[10], Marc Van den Eynde[11], Anne Jouret-Mourin[11], Jean-Pascal Machiels[11], Michael H. Roehrl [12], Prashant Bavi[13], Pamela S. Ohashi[14], Julia Y. Wang[14], Linh T. Nguyen[15], Seong Jun Han[14], Heather L. MacGregor[14], Sara Hafezi-Bakhtiari[13], Bradly G. Wouters[13], Giuseppe V. Masucci[16], Emilia K. Andersson[16], Eva Zavadova[17], Michal Vocka[17], Jan Spacek[17], Lubos Petruzelka[17], Bohuslav Konopasek[17], Pavel Dundr[17], Helena Skalova[17], Gerardo Botti[18], Fabiana Tatangelo[18], Paolo Delrio[19], Gennaro Cilberto[19], Michele Maio[20], Luigi Laghi[21], Fabio Grizzi[21], Tessa Fredriksen[1,2,3], Bénédicte Buttard[1,2,3], Mihaela Angelova[1,2,3], Angela Vasaturo[1,2,3], Pauline Maby[1,2,3], Helen K. Angell[1,2,3,22], Lucie Lafontaine[1,2,3], Nacilla Haicheur[4], Anne Berger[1,2,3,23], Christine Lagorce[1,2,3,24], Jeffrey P. Meyers[5], Ana M Todosi[25], Viorel Scripcariu[25], Boryana Papivanova[26], Mingli Xu[26], Tomonobu Fujita[26], Shoichi Hazama[27], Nobuaki Suzuki[27], Hiroaki Nagano[27], Kiyotaka Okuno[28],Toshihiko Torigoe[29], Noriyuki Sato[29], Kyogo Itoh[30], Tomohisa Furuhata[30], Ichiro Takemasa[30], Prabhu S. Patel[31], Hemangini H. Vora[31], Birva Shah[31], Jayendrakumar B. Patel[31], Kruti N. Rajvik[31], Shashank J. Pandya[31], Shilin N. Shukla[31], Yili Wang[32], Guanjun Zhang[32], Shoichi Hazama[27], Yutaka Kawakami[26], Francesco M. Marincola[33], Paolo A Ascierto[34], Daniel J. Sargent[5†], **Bernard A. Fox**[35,36], Jérôme Galon[1,2,3,*] Worldwide consortium-based validation of Immunoscore for the classification of colon cancer. The Lancet, 2018 May 26;391(10135):2128-2139, PMID: 29754777
141. Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, **Fox BA**, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I. Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review. PMID: 29996914
142. Andrew Weinberg, Thomas Duhen, Rebekka Duhen, Ryan Montler, Jake Moses, Tarsem Moudgil, Noel de Miranda, Cheri Goodall, Tiffany Blair, **Bernard Fox**, Jason McDermott, Shu-Ching Chang, Gary Grunkemeier, Rom Leidner, and Richard Bell. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018 Jul 13;9(1):2724. doi: 10.1038/s41467-018-05072-0. PMID: 30006565
143. Madonna G, Ballesteros-Merino C, Feng Z, Bifulco C, Capone M, Giannarelli D, Mallardo D, Simeone E, Grimaldi AM, Caracò C, Botti G, **Fox BA**, Ascierto PA. PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with

ipilimumab. Oncoimmunology. 2018 Sep 5;7(12):e1405206. doi: 10.1080/2162402X.2017.1405206. eCollection 2018. PMID: 30524879

144. van de Ven R, Hilton TL, Hu HM, Dubay CJ, Haley D, Paustian C, Puri S, Urba WJ, Curti BD, Aung S, **Fox BA**. Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer. Oncoimmunology. 2018 Sep 25;7(12):e1466766. doi: 10.1080/2162402X.2018.1466766. eCollection 2018. PMID: 30524883
145. Butterfield LH, Disis ML, **Fox BA**, Kaufman DR, Khleif SN, Wang E; Society for Immunotherapy of Cancer Immuno-Oncology Biomarkers: State of the Art workshop speakers. J Immunother Cancer. 2018 Dec 4;6(1):138. doi: 10.1186/s40425-018-0453-4. Review. PMID: 30514399
146. Wen ZF, Liu H, Gao R, Zhou M, Ma J, Zhang Y, Zhao J, Chen Y, Zhang T, Huang F, Pan N, Zhang J, **Fox BA**, Hu HM, Wang LX. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. J Immunother Cancer. 2018 Dec 18;6(1):151. doi: 10.1186/s40425-018-0452-5. PMID: 30563569
147. Maio M, Coukos G, Ferrone S, **Fox BA**, Fridman WH, Garcia PL, Lahn M, Provendier O, Russo V, Rüttinger D, Shalabi A, Trajanoski Z, Viallet J, Wolchok JD, Ibrahim R. Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy. Cancer Immunol Immunother. 2019 Jan;68(1):1-9. doi: 10.1007/s00262-018-2285-y. Epub 2018 Dec 18. PMID: 30564889
148. Wickenhauser C, Bethmann D, Feng Z, Jensen SM, Ballesteros-Merino C, Massa C, Steven A, Bauer M, Kaatzsch P, Pazaitis N, Toma G, Bifulco CB, **Fox BA**, Seliger B. Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. Methods Mol Biol. 2019;1913:13-31. doi: 10.1007/978-1-4939-8979-9_2. PMID: 30666596

## MANUSCRIPTS SUBMITTED

1. Traci L. Hilton, Christopher C. Paustian, Daniel P. Haley, Rieneke van de Ven, **Bernard A. Fox**, Hong Ming Hu and Sandra Aung Cell-Free Autophagosomes provide a novel non-genetic method to engineer leukocytes to express membrane proteins. *Under revision.*

## MANUSCRIPTS IN PREPARATION

1. Rachel E. Sanborn[1], Brian Boulmay[2], Rui Li[1], Kyle T. Happel[2], Sachin Puri[1], Christopher Paustian[1,3], Christopher Dubay [1], Sandra Aung[3], Brenda Fisher[1], Carlo B. Bifulco[1], Keith Bahjat[1], Yoshinobu Koguchi[1], Augusto C. Ochoa[2], Hong-Ming Hu[1,3], Traci L Hilton[3], Walter J. Urba[1] and Bernard A. Fox[1,3] Randomized ph II trial of allogeneic DPV-001 cancer vaccine alone or with adjuvant for curatively-treated stage III NSCLC.

## BOOKS and CHAPTERS

2. **Fox, B.A.**: The Insulin Receptor as a Marker of Activated Cellular Immunity in Experimental Allergic Encephalomyelitis, Master Thesis, University of Detroit, August 1978.
3. **Fox, B.A.**: Characterization of Monoclonal Antibodies Defining Macrophage Stage-Specific Cell Surface Antigens: Doctoral Dissertation, University Microfilms International, Ann Arbor, MI, 1985.
4. **Fox, B.A.**, Osterholzer, J.J., Mali, V., Schmogi, M.: Trafficking and survival of effector T cells in vivo. in Immunotherapy of Cancer with Sensitized T Lymphocytes. ed. Chang, A.E. and Shu, S. R.G. Landes Company, Austin. pg 91-109, 1994
5. **Fox, B.A.**, and Nabel, G.J.: The potential of gene transfer to alter the immune response to tumors in Tumor Immunology: Immunotherapy and Cancer Vaccines. ed. Dalgleish, A.G., and Browning, M., Cambridge University Press, pg300-326, 1996
6. Hu, H-M and **Fox, B.A**. Transfer of Genes Encoding Antigens, Co-Stimulatory Molecules, or Adhesion/Accessory Molecules as a Strategy to Augment the Anti-Tumor Immune Response. in Gene Therapy of Cancer. ed. Brenner, M.K. and Moen, R.C. Marcel Dekker Inc. New York, pg121-138, 1996.
7. Shahid, M.R., Robins, A., Rees R.C. and **Fox, B.A.** Immunogenicity of tumour associated antigens. In Cancer Immunology. Ed Robins R.A., and Rees, R.C., Immunology and Medicine Series, Kluwer Academic Publishers pg 1-26, 2001
8. Jensen S.M. and **Fox B.A**. Adoptive Cellular Immunotherapy of Cancer: A three-signal paradigm for translating recent developments into improved treatment strategies, in Tumor Immunology and Cancer Vaccines. Ed. Khleif, S. 2005
9. Rüttinger D, Hatz RA, Jauch KW, **Fox BA**. Current immunotherapeutic strategies in lung cancer. Surg Oncol Clin N Am.;16(4):901-18. Oct 2007
10. D.Ruttinger, R. Hatz, K-W. Jauch, **B.A. Fox**. Novel Strategies for Lung Cancer Immunotherapy. Chapter 121, in, Seventh edition, General Thoracic Surgery, Lippincott Williams & Wilkins. Pg 1529-1537, 2009
11. Winter H, Fox BA and Rüttinger D: Future of cancer vaccines. Chapter 43. in Cancer Vaccines Methods and Protocols. *In Press*.
12. Paustian C, Jensen SM, Church S, Puri S, Twitty C, Hu H-M, Curti BD, Urba WJ, Puri RK, and **Fox BA**. Targeting Regulatory T Cells and Other Strategies to Enable Cancer Vaccines. In Cancer Vaccines, from Research to Clinical Practice, Second Edition. (2011, Hardcover, Revised, Informa Healthcare, ISBN-10: 1841848298 | ISBN-13: 9781841848297
13. Jensen S, Paustian C and **Fox BA**. Employing T cell Homeostasis as an Anti-Tumor Strategy, in Advances in Tumor Immunology and Immuotherapy, ed. J Rosenblatt, E Podak, G Barber and A Ochoa. Springer, 2014 ISBN: 978-1-4614-8808-8
14. Feng, Z, Bifulco C.B., Leidner, R, Bell, R.B., Fox, B.A. Immunotherapy in Head and Neck Cancers. In Targeting Oral Cancer, Ed. Fribley, A., Springer, *in press*

## TECHNICAL CHAPTERS IN BOOKS

1. **Fox, B.A.**: Retro-orbital blood collection. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs. 24-25, 1989.
2. **Fox, B.A.**: Cell separation by panning. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs. 60-61,1989

3. **Fox, B.A.**: Perroll gradient cell separation. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs. 62-63,1989.
4. **Fox, B.A.**: Generation of rabbit antisera. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pg. 70, 1989.
5. **Fox, B.A.**: Generation of monoclonal antibodies. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs. 73-74,1989.
6. **Fox, B.A.**: $^{3}$H-Thymidine proliferation assay. In: Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz. Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs. 100-101,1989
7. **Fox, B.A**: Mixed lymphocyte reaction, Laboratory protocols for the immunotherapy of cancer. Editors, R.B. Cameron and S.L. Schwarz, Published by Surgery Branch, National Cancer Institute, National Institutes of Health, pgs 102-103, 1989

**LAY PRESS**

1. D.Ruttinger, **B.A. Fox** and H-M. Hu. Getting to the bone: Fighting skeletal cancer metastases with specific T lymphocytes. Pharma Focus Asia 7: 26-29. 2008

**WEB BASED EDUCATIONAL MATERIALS**

1. Living Medical Textbook, Projects in Knowledge. Oncology – Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition I, 2008 Http://WWW.living medicaltextbook.org/Oncology/Immunology in Review and Tumor-Fighting T-Cells
2. Defining the Critical Hurdles in Cancer Immunotherapy. iSBTc / Society for Immunotherapy of Cancer (SITC) 2010 Annual Meeting. http://www.sitcancer.org/meetings/am10/presentations/index.php?filename=Fox-BM10_secure.pdf
3. Living Medical Textbook, Projects in Knowledge. Oncology – Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition II, 2012 Http://WWW.living medicaltextbook.org/Oncology/Immunology in Review and Tumor-Fighting T-Cells
4. Colon Cancer Immunotherapy Study Evaluating the Immunoscore. Society for Immunotherapy of Cancer, 2012 Workshop. http://www.sitcancer.org/meetings/am12/presentations/index.php?filename=WK-fox_slides.pdf http://www.youtube.com/watch?v=uS7oOGke9aM
5. Update Session: Immunoscore. Society for Immunotherapy of Cancer, 2013 Annual Meeting. www.sitcancer.org/meetings/am13/presentations/index.php?filename=560ec16680ac4d97998666f02ae2260d1d
6. Advisory Board: Understanding Cancer Immunotherapy: Where information equals hope, Patient Resources, 2014. http://www.sitcancer.org/UserFiles/file/understanding-cancer-immunotherapy-patient-guide-2014.pdf
7. Cancer immunology: Charting the course forward for immunoprofiling. American Association for the Advancement of Science Webinar, April 1, 2015 http://webinar.sciencemag.org/webinar/archive/cancer-immunology

8. Second Edition: Advisory Board: Understanding Cancer Immunotherapy: Where information equals hope, Patient Resources, 2015. http://www.sitcancer.org/UserFiles/file/2015ImmunotherapyGuideSecondEdition.pdf
9. The Beginning of the End: Immunoprofiling Coming of Age. Originally broadcast April 27, 2017 Nature.com Webcast http://www.workcast.com/register?cpak=4583771895602991&referrer=HOMEPAGE_PERKINELMER_1704

**INVITED AND GUEST LECTURES**

1. New Leads for Improving Immunotherapy; Based on Experimental Models, Alberta Cancer Board Annual Research Symposium, keynote address, Kanaskis, Alberta, November 25, 1989
2. Overview of Animal Models Used for IL-2 Therapy: Where are they Taking Us in the 1990's. Invited lecturer, Frankfurt International Interleukin-2 Symposium, Goethe Universitat, Frankfurt, Germany, March 23, 1990
3. Retroviral Gene Transduction of Murine Tumor Infiltrating Lymphocytes, Guest lecturer, Mario Negri Cancer Institute, Milan, Italy, March 29, 1990
4. Retroviral Mediated Gene Transfer of Cytokine Genes into T Cells with Antitumor Properties, Guest lecturer, Dr. Daniel Den Hoed Cancer Center, University of Rotterdam, Netherlands, November 13, 1990
5. Utilization of T Cell Clones to Study the Mechanism of T Cell-Tumor Interactions, Guest lecturer, Julius-Maximilians-Universitat, Wurzburg, Germany, November 14, 1990
6. New Experimental Models for Cytokine Research, International Symposium, New Developments in Basic and Clinical Research in Renal Cell Carcinoma, Invited Lecturer, Ruprecht-Karls-Universitat, Heidelberg, Germany, November 17, 1990
7. New Leads for Improving Immunotherapy with Gene Transfer, Invited lecturer Warner Lambert, Parke Davis Research Laboratory, Ann Arbor, MI, April 23, 1992
8. New Leads for Improving Immunotherapy with Gene Transfer, Guest lecturer, Department of Hematology-Oncology, Goethe Universitat, Frankfurt, Germany, August 18, 1992
9. New Approaches to the Immunotherapy of Cancer Using Gene Transfer, Invited lecturer, International Symposium on Gene Therapy and Genetic Engineering, Chosun University, Kwang-Ju, Seoul, Republic of Korea, November 2, 1992
10. New Approaches to the Immunotherapy of Cancer Using Gene Transfer, Invited lecturer, Sixth Annual Medical Scientist training Program Mini-Symposium, "Genetic Engineering and Human Disease", Health Sciences Center, SUNY at Stony Brook, January 29, 1993
11. Gene Therapy of Cancer: Experimental and Clinical Studies. Invited lecturer, Sixth Annual University of Nebraska Medical Center Immunology Symposium, "Current and Future Strategies for Immunoregulation in Transplantation", April 19-20, 1993
12. Gene Transfer for the Immunotherapy of Cancer, Two different Approaches, Invited lecturer, IBC's Second Annual Conference on Gene Therapy, Washington D.C. June 21-22, 1993
13. Allogenization of the Cancer Cell by Direct Gene Transfer, Invited lecturer, "Xenogenization of the Cancer Cell: From Basics to the Clinic" NCI-Frederick Cancer Research and Development Center, Frederick, MD September 13-14, 1993
14. Immunotherapy of Cancer by In Vivo Gene Transfer into Tumors, Invited lecturer, First International Conference on Gene Therapies and Vaccines for Cancer: BioEast'94 Washington D.C. January 25 - 27, 1994.

15. HLA-B7 in RCC -- Gene Transfer Studies, Invited lecturer, Third International Symposium on The Biology of Renal Cell Carcinoma, Ritz-Carlton / Cleveland Clinic, Cleveland, OH March 6-8, 1994
16. Genetic Modification of Tumor Vaccines, Invited lecturer, Julius-Maximilians-Universitat, Wurzburg, Germany, June 9, 1994
17. Genetic Modification of Tumor Vaccines, Guest Lecturer, Division of Immunology, Hospital General Univeritario "Gregorio Maranon", Complutense University of Madrid, June 13, 1994
18. Tumor Immunotherapy, Invited lecturer, Gene Therapy and Cancer, Institute of Molecular and Cell Biology, National University of Singapore, Singapore, August 15, 1994
19. Immunotherapy of Cancer by Allogeneic HLA/MHC Class I Gene Transfer into Tumors: Results of Clinical and Animal Studies. Invited lecturer, 16th Annual Ohio Valley Lake Erie Association of Cancer Centers, "New Insights for Cancer Therapy Arising from Translational Research", University of Pittsburgh, Pittsburgh, PA, October 14, 1994
20. Direct Gene Therapy for Cancer, Invited lecturer, Society for Biological Therapy, Silverado, Napa Valley, CA. October 28, 1994
21. Immunotherapy of Cancer by In Vivo Allogeneic HLA/MHC Class I Gene Transfer Into Tumors: Results of Clinical and Animal Studies. Invited lecturer. Septièmes Entretiens du Centre Jacques Cartier, "Gene Therapy". Annecy, Rhône-Alpes, France, December 1, 1994.
22. Mechanisms for Direct Gene Transfer. Invited lecturer. William Harvey Research Conferences, "Genes and Disease: Opportunities for New Therapies and Diagnostics". London, England. December 5, 1994
23. Gene Therapy with Non-Viral Vectors. Invited lecturer. International Symposium: New Developments in Basic and Clinical Research in Renal Cell Carcinoma. Ruprecht-Karls-Universitat, Heidelberg, Germany, May 5-6, 1995
24. Antigen-Based Strategies for the Gene Therapy of Cancer: Pre-Clinical and Clinical Trials. Guest lecturer, Albert-Ludwigs- Universitat, Freiburg, Germany, May 8, 1995
25. Antigen-Based Strategies for the Gene Therapy of Cancer: Pre-Clinical and Clinical Trials. Invited lecturer, European Cancer Centre, Department of Pathology, Free University Hospital, Amsterdam, The Netherlands, May 15, 1995
26. Allogeneic MHC/HLA Antigen-Based Strategies for the Gene Therapy of Cancer: Pre-Clinical and Clinical Trials. Department of Molecular and Medical Genetics, Oregon Health Sciences University School of Medicine, Portland, Oregon, October 4, 1995
27. Allogeneic MHC/HLA Antigen-Based Strategies for the Gene Therapy of Cancer: Pre-Clinical and Clinical Trials. Department of Chemistry, Biochemistry, and Molecular Biology, Oregon Graduate Institute of Science and Technology, Portland, Oregon, October 20, 1995
28. Treatment of Malignant Melanoma: Present and Future Prospects. Grand Rounds, Department of Surgery, Oregon Health Sciences University, Portland, Oregon, February 5, 1996
29. Treatment of Malignant Melanoma: Present and Future Prospects. Grand Rounds with Dr. J. Vetto, St. Vincent Medical Center, Portland, Oregon, February 20, 1996
30. Current Status of Gene Therapy Trial, Second Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, J.W. Marriott Hotel, Washington, D.C., April 20, 1996
31. Advances in Gene Therapy, University of Indiana, Indianapolis, Indiana, April 26, 1996
32. Allogeneic Antigen-Based Strategies for the Gene Therapy of Cancer: Pre-Clinical and Clinical Trials. Immunology and Immunotherapy of Metastasis, Lake Tahoe, California, May 12, 1996
33. Lipofected Autologous Tumor Cell Vaccine strategies- What? Why? How? Genetic Therapy Inc, Gaithersburg, MD, November 8, 1996

34. Experiences with Vaccine Strategies for the Treatment of Cancer, Cleveland Clinic Foundation, Cleveland, OH, November 15, 1996
35. Adoptive Immunotherapy Using a Lipofected Tumor Vaccine for the Sensitization of Tumor-specific T cells. Tumor Vaccine and Cell Therapy Working Group, Hotel Del Coronado, San Diego, CA, April 12, 1997
36. Combining Gene Transfer and Adoptive Immunotherapy Strategies for the Treatment of Cancer, Cantab Inc, Cambridge, UK, May 1, 1997
37. Adoptive Immunotherapy Using Vaccine-Primed T Cells: Pre-Clinical and Clinical Experience. Tenovus Institute, University of Southampton, Southampton, UK, May 2, 1997
38. Combining Gene Transfer and Adoptive Immunotherapy Strategies for the Treatment of Cancer. St Georges Hospital Medical School, University of London, London, UK, May 6, 1997
39. Allo-Modification of Tumor Vaccines for the Treatment of Melanoma at Biological Therapy of Cancer, Biological Therapeutics Development Group of the European Organization for Research and Treatment of Cancer, Ludwig-Maximilians-Universitat, Munich, Germany, June 13, 1997
40. Translating animal studies into clinical trials: Why bother with the mice? Northwest Biotherapeutics, Seattle, WA, August 8, 1997
41. Immune deviation: preclinical and clinical observations. Tumor Vaccine and Cell Therapy Working Group. UCSF / Mt. Zion Cancer Center, San Francisco, CA, April 18, 1998.
42. Cytokine profile of tumor vaccine-draining lymph node T cells predicts tumor immunogenicity, 10th International Congress of Immunology, New Delhi, India, October 30, 1998
43. Recent developments in vaccine strategies, Indian Medical Association, Sitapur Branch, Sitapur, India, November 7, 1998
44. Immune deviation: A mechanism for tumor vaccine failure. Central Drug Research Institute, Lucknow, India, November 9, 1998
45. Examining the mechanism of T cell-mediated tumor regression. Tenovus Cancer Research Laboratory, Southampton, UK, November 30, 1998
46. Immune Deviation: A Possible Mechanism to Prevent Tumor Destruction. British Society for Immunology 6th Annual Congress, Harrogate, UK, December 1-4, 1998
47. GM-CSF gene modified tumor vaccine primes T cell with therapeutic activity from tumor-bearing mice. Cantab Investigators meeting, Harrogate, UK, December 4, 1998
48. Immune deviation: A mechanism for tumor vaccine failure, FDA/NCI Workshop on Tumor Vaccines. Masur Auditorium, National Institutes of Health, Bethesda, MD, December 10-11, 1998.
49. Examining the immune response in sentinel lymph nodes of mice and men. First International Congress on Sentinel LN in the Diagnosis and Treatment of Cancer, Amsterdam, The Neatherlands, April 8, 1999
50. Effector Mechanisms in Tumor Regression Free, Universitat, Dutch Cancer Institute, Amsterdam, The Neatherlands, April 8, 1999
51. Immune deviation. Tumor Vaccine and Cell Therapy Working Group. Philadelphia, PA, April 10, 1999.
52. Monitoring immune responses in mice and men: What does it tell us? Cell Genesys, Foster City, CA, May 11, 1999
53. Introduction to melanoma vaccines, Chiron/Providence Cancer Program educational program for oncology nurses, Pazzo Ristorante, May 17, 1999

54. Effector Mechanisms in T cell-Mediated Tumor Regression: Can this Information Help Us Design and Monitor a New Generation of Clinical Trials. Department of Immunology, Wayne State University School of Medicine, Detroit, MI, Sept 13, 1999
55. Tumors, are they invisible or do they coerce the host into making a nondestructive immune response: results from preclinical and clinical studies. Grand Rounds, Department of Urology, State University of New York, Health Science Center, Syracuse, NY September 16, 1999
56. Examining the immune response in sentinel lymph nodes of mice and men. Shanghai Medical University, Shanghai, China. October 22, 1999
57. Critical components in the priming of antitumor immune responses and the T cell-mediated destruction of tumor in vivo, Seminar co-lecturer with H-M. Hu and H. Winter. Beijing Medical University, Beijing, China. October 29, 1999
58. Critical components in the priming of antitumor immune responses and the T cell-mediated destruction of tumor in vivo, Seminar co-lecturer with H-M. Hu and H. Winter. Xi'an Medical University, Xi'an, China. November 2, 1999
59. Effector Mechanisms in T cell-Mediated Tumor Regression: Ludwig Institute for Cancer Research, , Lausanne branch, CHUVLausanne, Switzerland, July 4, 2000
60. Analysis of Sentinel Lymph Nodes Following Vaccination: A Possible Predictor of Therapeutic Efficacy? Society of Nuclear Imaging & Drug Development Conference, Natcher Auditorium, NIH, Bethesda, MD, October 23-25, 2000
61. Examining Critical Molecular Interactions During in Vivo Priming of Therapeutic CD8+ T cells. Tumor Immunology Program Retreat, University of Michigan, November 13, 2000
62. How Do T Cells Mediate Tumor Regression? Grand Rounds, Moffitt Cancer Center, Tampa, FL January 24, 2001
63. How Do T Cells Mediate Tumor Regression? University of Arizona, Tucson, AZ February 9, 2001.
64. Examining Critical Molecular Interactions During in Vivo Priming of Therapeutic $CD8^+$ T cells. Medicine Branch, NCI, NIH, Bethesda, MD, March 16, 2001
65. Critical Molecular Interactions for Efficient Vaccination, FDA USDA Conference on Tumor Vaccines, USDA center for veterinary biologics, Ames, Iowa, April 12-13, 2001
66. Developing and Monitoring Clinical Trials for Melanoma, Breast, Renal and Non-Small Cell Lung Cancer. Országos Onkológiai Intézet (National Oncology Institute), Budapest, Hungary, September 7, 2001.
67. Gene-modified Tumor Vaccines – from Animal Models to Therapeutic Strategies. Klinikum Grosshadern, Ludwig-Maximilians-University, München, Germany, September 12-15, 2001
68. How Do T Cells Mediate Tumor Regression? Institute of Molecular Genetics, Academy of Sciences of the Czech Republic, Prague, Czech Republic, January 14, 2002
69. How Do T Cells Mediate Tumor Regression? University of Freiburg, January 28, 2002
70. Monitoring the immune response to vaccination: Studies of melanoma, breast and non small cell lung cancer patients. Istituto Tumori, Milan, Italy, February 6, 2002
71. Translating Basic Science into clinical trials for melanoma, renal, breast and NSCLC - A reciprocating process. Ospedale S. Luigi Gonzaga, Turin, Italy February 7, 2002
72. Do Cytolytic T Cells Mediate Tumor Regression or do Cytokines make all the Difference? Ingenium Inc. Munich, Germany February 11, 2002
73. Do Cytolytic T Cells Mediate Tumor Regression or do Cytokines make all the Difference? Immunology Department, University of Regansburg, Regansburg, Germany, February 12, 2002

74. Using anti-CD3 activation and IL-2 to expand T cells and monitor tumor-specific T cell function. Tegernsee Conference on the Immunotherapy of solid Cancers. Tegernsee, Germany, July 3-5, 2002
75. Vaccination of Lymphopenic Hosts, DFG Cancer Immunology Retreat, Wilbad Kreuth, Bavaria, Germany, September 29, 2002
76. Is Effective Adoptive Immunotherapy just around the corner? Or, are mouse models leading us astray? A review of one Institute's experiences, Xcyte Inc, Seattle, WA January 10, 2003.
77. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Invited lecturer, Keystone Symposia, Tumor Immunology, February 17-23, 2003
78. Manipulating the Host Response to Autologous Tumor Vaccines and the Role of Animal Models in Tumor Vaccine Development, Development of therapeutic Cancer Vaccines Conference, Los Angeles, CA April 27-29, 2003
79. Cancer Immunotherapy. Oregon Health and Science University, invited lecturer, Portland, OR, May 15, 2003
80. Exploiting Homeostatic Proliferation to Augment Antitumor Immunity, Eighth UCLA Human Gene Medicine Symposium, Invited Lecturer, Los Angeles, CA. May 19, 2003
81. T cell-mediated tumor regression: How does it work and how can it be augmented. Invited lecturer, University of Nebraska Medical Center, Invited Lecturer, Omaha, NE. May 22-24, 2003.
82. Exploiting Homeostasis-driven Proliferation to Augment Antitumor Immunity, invited lecturer, Department of Surgery, University of Chicago, June 5, 2003
83. Preclinical advances in cancer immunotherapy are coming to the clinic this year: This should include your patients! Invited lecturer to research nurses and oncologists in Portland, Chiron educational program. Portland, OR. June 9, 2003
84. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Invited lecturer, 7th International Meeting and 1st World Congress Biotherapy of Cancer - From Disease to Targeted Treatment, Munich, Germany, September 10-13, 2003
85. Exploiting Lymphopenia to Reboot the Immune Response to Cancer. Invited lecturer, Southwest Oncology Group (SWOG). Immunomolecular Therapeutics Committee, Seattle, WA, October 3, 2003
86. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Invited lecturer, Clinical & Translational Seminar, Loyolla University Medical Center, Cardinal Bernardin Cancer Center, Maywood, IL. November 3, 2003.
87. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Norris Cancer Center, Medical Oncology Research Laboratory Seminar, University of Southern California, Los Angeles, CA. December 8, 2003.
88. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Invited speaker, Center for Immunotherapy Seminar Series, University of Connecticut. January 29, 2004.
89. Preclinical immunotherapeutic studies with tumor vaccine-draining lymph node T cells. Invited lecturer, Workshop on Immunotherapy in cancer, A transatlantic Cancer Center Meeting, VU Institute for Cancer and Immunology V-ICI and Cancer Center, Amsterdam, February 26, 2004.

90. Exploiting Lymphopenia to Reboot the Immune Response to Cancer. Invited lecturer, Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA. March 3, 2004.
91. Preclinical Immunotherapeutic Studies with Tumor Vaccine-Draining Lymph Node T Cells. Invited Lecturer, Sabin Vaccine Institute, Walker's Cay, Bahamas. March 10-13, 2004
92. Critical evaluation of predictive and monitoring tests in Immunotherapy BDA. Strategies for early clinical development of Molecular Targeted Therapy of Cancer. Innsbruck, Austria, March 17, 2004
93. Vaccination of Reconstituted Lymphopenic Hosts with Genetically Modified Tumor Cells Generates T cells for Effective Adoptive Immunotherapy. International Meeting on Cancer Vaccines, Istituto Superior di Sanita, Rome, Italy. April 19, 2004.
94. Chemo-immunotherapy: Recent developments provide a new paradigm and an innovative clinical trial for prostate cancer. Grand Rounds, SUNY Upstate, Syracuse, NY, May 20, 2004
95. Vaccination of Reconstituted Lymphopenic Hosts: Translating an Effective Preclinical Strategy into Clinical Trials. Invited lecturer, Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI. Aug 25, 2004
96. Lymphoid reconstruction: A new approach to "re-boot" the anti-tumor immune response of cancer patients. Loyolla University Medical Center program at Hamburger University, Oak Brook, IL. September 17, 2004
97. Exploiting lymphopenia to "re-boot" the immune response of patients with cancer. Invited lecturer, Adoptive immunotherapy session, Annual meeting of the International Society for the Biological Therapy of Cancer, San Francisco, CA. Nov 5, 2004
98. T cell-Mediated Tumor Regression: How it Works and How it can be Augmented. Invited lecturer, Annual meeting of the Society for Melanoma Research, Phoenix, AZ, Nov 14, 2004
99. Vaccine Induced Immunity in Lymphopenic hosts. GVAX® Focus Panel Discussion, Baltimore, MD. January 27, 2005
100. Translating Basic Science into Clinical Trials for Cancer: A Reciprocating Process. Invited lecturer, Spring Symposium on Translational Therapeutics, Hollings Cancer Center, Medical University of South Carolina. Citadel Alumni Center, Charleston, SC. March 11, 2005
101. The Uses and Mechanisms of lymphodepletion (in cancer vaccine strategies). Invited lecturer, Keystone Symposia – Basic Aspects of Tumor Immunology, Keystone, Colorado. March 19-25, 2005
102. Immunotherapy. Invited lecturer, Oregon Health and Science University, Portland, OR. May 11, 2005
103. RLP Vaccine Strategies at the Earle A. Chiles Research Institute, Genentech sponsored dinner meeting, Heathman Hotel. Portland, Oregon, June 9, 2005
104. Defining and Augmenting the Therapeutic Antitumor Immune Response, Seventh Annual Cancer Vaccines and Immunotherapy Colloquium, Cold Spring Harbor Laboratory, Long Island, New York. June 21-24, 2005.
105. Vaccines in Reconstituted Lymphopenic Hosts, Second Tegernsee Conference on the Immunotherapy of solid Cancers, Rottach-Egern, Germany. June 29 -July 1, 2005
106. Autologous Tumor Vaccines, Invited lecturer, Satellite Symposium: Critical Questions in Melanoma Vaccine Development (Sponsored by Serono Symposia International), The sixth World Congress on Melanoma, Vancouver, BC, Canada. September 6-10, 2005
107. New Strategies of Cancer Immunotherapy, Invited lecturer and Guest Professor, Xi'an Jiaotong University, Xi'an, China. October 14, 2005.

108. Exploiting Lymphopenia to Augment Vaccine Efficacy, Invited speaker, Keystone Symposia: Santa Fe, NM. January 19, 2006
109. Combining chemo-induced lymphopenia, adoptive transfer of Peripheral T cells and active-specific immunotherapy to augment the anti-cancer immune response: Preclinical and clinical studies. Invited speaker, Immunotherapy of Cancer: Challenges and Needs, Istituto Superiore Di Sanita, Rome, Italy. May 24-25, 2006
110. "New" Chemoimmunotherapy for Cancer: Rebooting the immune system without regulatory T cells - Preclinical and clinical studies. 8th International Symposium from Disease to Targeted Therapy co-organized by Biotherapy Development Association, European Society for Medical Oncology and the National Cancer Institute, Dresden, Germany. June 21 – 24, 2006
111. Novel Use of HuMax-CD4 (Zanolimumab) in Cancer Vaccine Strategies. Lung Cancer Immunotherapy Group, Klinikum Grosshadern, Ludwig-Maximilians-University, Munich, Germany. June 29, 2006.
112. Regulating regulatory cells: Novel preclinical strategies headed for the clinic. Invited speaker,
113. Perspectives in Melanoma X, Society for Melanoma Research and European Organization for the Research and Treatment of Cancer, Noordwijk, The Netherlands. September 14-16, 2006
114. Uncovering antitumor immunity with HuMax-CD4 (Zanolimumab), Invited lecturer, Serono, Geneva, Switzerland. September 18, 2006.
115. Therapeutic Approaches Utilizing Lymphodepletion, Invited lecturer, Sabin Cancer Vaccine Colloquium, Washington DC. November 9-11, 2006
116. Exploiting Lymphopenia to Augment GVAX Efficacy: Updates on Prostate GVAX Clinical Trial and Preclinical Studies, Invited lecturer. GVAX Focus Panel, Baltimore, MD March 22-23, 2007.
117. Uncovering therapeutic anti-tumor immunity with anti-CD4., Serono Advisory Board Meeting, Boston, MA. June 15, 2007
118. Regulating Regulatory T cells: a novel Strategy to Augment Anti-tumor Immunity in Mice and Humans. Invited lecturer. Reno, NV. October 10, 2007
119. Cyclophosphamide and Fludarabine Treatment Prior to Reconstitution with PBMC and Vaccination Does Not Result in a Reduced Frequency of Circulating FoxP3$^{+}$ T cells in Men with Prostate Cancer. PCF Annual Scientific Retreat. Oct 11-13, 2007
120. Regulating Regulatory T Cells: A Novel Strategy to Augment Anti-tumor Immunity. Invited lecturer, AACR-NCI-EORTC International Conference. October 22-26, 2007
121. Phenotype and Functional Characterization of long-term gp-100-Specific memory CD8+ T cells. NIH Biomarkers Conference. Bethesda, MD. November 26-27, 2007
122. Rethinking the Wall Street-Directed Approach to Drug Development--Why Scientists Must Influence the Decision Making Process. Invited lecture. Center for Professional Development. Department of Science and Engineering, OHSU. January 22, 2008
123. Tumor-induced Regulatory T cells: Cancer's "Darth Vader" - Strategies to tip the balance in favor of the "Force" (mice and people). Invited lecturer. Medical University of South Carolina, Charleston, SC. March 26, 2008
124. Human anti CD4 MAB Zanolimumab: A Universal Adjuvant for Cancer Immunotherapy? Genmab Zanolimumab (Humax-CD4) for combination trial. Copenhagen, DK. May 14, 2008
125. Augment Therapeutic Anti-Cancer Immunity in Mice and Humans. Invited lecturer. CIMT-Cancer Immunotherapy meeting. Mainz, Germany. May 15-16, 2008.
126. Discussant, Developmental Therapeutics: Immunotherapy, ASCO Annual Meeting, Chicago, Il, May 30-June 03, 2008

127. Translational Cancer Immunotherapy. Invited lecturer. OHSU MD, PhD Student Retreat. Timberline Lodge, Government Camp, Oregon. October 11, 2008.
128. Monitoring tumor-specific immune responses to undefined antigens. Invited lecturer. Immunotherapy Treatments and Markers in Clinical Trials Phase II and III. US-Japanese workshop on immunological molecular markers in oncology. Waikola, HI. March 23-24, 2009
129. Engineered T Cells: Cell Processing Related Issues. Moderator and invited lecturer. "Converging Concepts in Cell Therapy" National Heart Lung and Blood Institute Workshop, NIH. April 23-24, 2009, Bethesda, MD .
130. Combination Immunotherapy: Translation of Preclinical Strategies into Patients with Cancer. Invited lecturer. Karmanos Cancer Institute, Detroit, MI. June 22, 2009
131. Manipulating Regulatory T-cells to Enhance Anti-tumor Immunity. Tegernsee, Germany, July 2-4, 2009
132. Combination Immunotherapy: Translation of Preclinical Strategies into Patients with Cancer. Mankind Seminar, Los Angeles, CA 03/10/2010
133. Combination Immunotherapy: Translation of Preclinical Strategies into Patients with Cancer. Invited lecturer. 8th NCEV Workshop, Stockholm, Sweden March 29-30, 2010.
134. Combined adoptive and active immunotherapy. 5th Meeting on Combined Biotherapy of Cancer. Milan, April 9, 2010.
135. Immunotherapy: Data and some issues for our field. Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, 606-8501, Japan, August 31st, 2010
136. Regulatory Cells in Cancer: Three Strategies To "Out Fox" Them. Prof Rik Scheper Retirement Symposium, Vriej University, Amsterdam, The Netherlands, November 4th, 2010
137. Immunotherapy: Data and some issues for our field. VUMC Fellows discussion group, November 4th, 2010
138. Cancer-induced Regulatory T cells: Melanoma's Darth Vader – Strategies to Monitor and Tip the Balance in Favor of the "Force" Melanoma Research: A Bridge Naples-USA, Naples, December 6-7, 2010
139. Translating and Monitoring Combination Immunotherapy: Canadian Cancer Immunotherapy Consortium (CCIC) Lake Louise, Alberta, Canada, April 8th, 2011.
140. Translating combination immunotherapy to patients with cancer. Molecular Microbiology and Immunology Department Retreat, OHSU, Portland, OR April 29th, 2011
141. Cancer Immunotherapy 2011: Current Status – Future Hurdles. CSCO-SITC-CAHON Joint Symposium. The 14th CSCO Annual Meeting, Xiamen, September 14-16, 2011.
142. Cancer Immunotherapy 2011: Current Status - Future Hurdles. Shandong University, Jinan, China, September 17, 2011
143. Exploiting Autophagy to Improve Immunotherapy of Cancer. The 12th Conference on Tumor Biotherapy, Chinese Society of Tumor Biotherapy, Jinan, October 8-10, 2011
144. The Future of Personalized Medicine, Oregon Bioscience Association annual meeting, Portland, Oregon, September 28, 2011
145. Challenges for Cancer Immunotherapy in 2011 and Strategies to Unravel Secrets of the Anticancer Immune Response, Fudan University, Shanghai, China. October 14, 2011
146. Exploiting Autophagy to Improve Immunotherapy of Cancer. New Perspectives in the Immunotherapy of Cancer, ESCII/NIBIT meeting, Sienna, Italy. October 19-22, 2011
147. Targeting Regulatory Cells to Enable Cancer Vaccines Melanoma Research: a bridge from Naples to the World, Naples December 5-6, 2011,

148. Inflammation and Immune Signatures in Cancer: The Good, the Bad and the Challenge for Immunologists. Knight Cancer Institute Tumor Immunology Retreat, OHSU, Portland, OR December 15, 2011
149. The Immunoscore: A New Possible Approach in the Classification of Cancer. Invited speaker. Naples, February 13, 2012
150. World Immunotherapy Council (WIC): A short History of the WIC. Hyatt Regency Curacao, Curacao, The Dutch Caribbean, February 20th, 2012
151. Immune Profiling, invited presentation to advisory panel. Ventana, Tucson, AZ March 25th, 2012
152. Exploiting Autophagy to Improve Immunotherapy of Cancer. Tumor Vaccine and Cell Therapy Working Group, Loyola University Medical School, March 30th, 2012
153. SITC Immunoscore Taskforce, Presentation to SITC panel, ASCO, June 4th, 2012
154. Cancer Vaccines. Invited talk. 2012 Nanjing Pharmaceutical Conference, Nanjing, China. June 19th, 2012
155. Immunoscore. Invited talk, Roche, Penzberg, Germany, June 28th, 2012
156. Immunoscore as a prognostic *(predictive?)* biomarker of response, invited lecture, CSCO-SITC-CAHON Second Joint Symposium, 15th Annual Meeting Chinese Society for Clinical Onccology, September 19th-23rd (20th), 2012, Beijing, China
157. The Immunoscore: A proposal for a new classification of Cancer in the Era of immunotherapies and - A Strategic View of Immunoscore, (Combined talks – Jerome Galon unable to attend). Annual meeting Society for Immunotherapy of Cancer, October 24, 2012
158. Lung Cancer Immunobiology and Immunoscore: A New Classification System for Cancer? Mayo Clinic School of Medicine Educational Conference on NSCLC. November 16-17, 2012
159. Vaccine Strategy Targeting Antigens Expressed by Tumors in their Microenvironment. Melanoma Bridge Meeting, Naples, Italy, December 2nd-4th, 2012
160. Applications and Understanding of Immunoscore: What it tells us and what we need to do. Immunotherapies and Cancer Vaccines session- CQ3486, Brussels, Belguim, December 7th, 2012
161. Exploiting Autophagy to Improve Immunotherapy of Cancer. Invited lecture, University of Pittsburgh Cancer Institute Lecture, Pittsburgh, PA, February 5th, 2013.
162. Biologics: Drug Development. Invited talk, Oregon BioScience Association Conference, Portland, OR, March 20, 2013.
163. Immunoscore and Autophagy: Transforming the Practice of Oncology. Invited Lecture, Center for Biologics Research (CBER), Food and Drug Administration (FDA), Bethesda, MD, March 7, 2013
164. An Immunoscore for Melanoma. Melanoma Advisory Board, Ventana/Roche, Tucson Symposium, Tucson, AZ, March 11-13, 2013
165. How Well Preclinical Models Predict Toxicity and Efficacy. Invited lecture, Cancer Immunotherapy Clinical Trials: Concepts and Challenges. Masur Auditorium, Building 10, NIH, Bethesda, MD, April 4-5, 2013
166. Exploiting Autophagy to Improve Immunotherapy of Cancer, Cancer Center Grand Rounds, Moffitt Cancer Center, Tampa, FL, April 11, 2013
167. Generating and Augmenting Therapeutic Anti-Cancer Immunity, Invited lecture, Agonox Maui Conference, Mackenna Resort, Maui, HI, May 1, 2013
168. Tumor Autophagosome-Based Cancer Vaccine Combination Immunotherapy Provides Therapeutic Immunity Against Established Breast Cancer. Tumor Vaccine and Cell Therapy

Working Group, Cancer Center, University of Hawaii Medical School, Honolulu, HI, May 2, 2013

169. The Transformation of Oncology: A Strategic view of Immunoscore and Immunoprofiling, Invited lecture, International (Guangzhou) Forum on Cancer. Guangzhou, China, May 25, 2013
170. Exploiting Autophagy to Improve Immunotherapy of Cancer, Cancer Center Grand Rounds, Carbone Cancer Center, University of Wisconsin, Madison, WI, June 1, 2013
171. The World Immunotherapy Council: Immunotherapy without Borders, Milan, Italy, August 25, 2013.
172. UbiVac: A Clinical Stage Immunotherapy Company. Oregon Bioscience Association Annual Meeting, Lake Oswego, OR September 18, 2013
173. Next Generation Clinical Trials: Transforming the practice of Oncology. Oregon Bioscience Association Annual Meeting, Lake Oswego, OR September 18, 2013
174. Ethics in Research. Course in Bioethics, University of Portland, Portland, OR, September 30, 2013
175. The Transformation of Oncology: A Strategic View of Immunoscore, Immunotherapy and the Next Decade. Knight Cancer Institute Retreat, The Resort at the Mountain,Welches, OR, October 17, 2013
176. The Transformation of Oncology: A strategic view of Immunoscore and Immunotherapy, Invited lecture, November 3, 2013 JNJ lecture Springhouse, PA
177. CITN: Immunoscore Update, CITN Investigators meeting at the Society for Immunotherapy of Cancer Meeting. National Harbor, MD. November 6, 2013
178. Update Section: Immunoscore. Society for Immunotherapy of Cancer Annual Meeting. National Harbor, MD. November 7, 2013
179. The Practice of Oncology is About to Undergo a Transformation. Melanoma Tumor Board, PPMC, December 12, 2013
180. The Immunoscore: Strategic Considerations for the Next Decade. SITC-SIDRA Symposium on Immunoscore 2014, Doha, Qatar, January 22-23, 2014
181. Exploiting Autophagy to Improve Immunotherapy of Cancer. School of Medicine Seminar Series, Oregon Health & Science University, Portland Oregon, January 27, 2014
182. Exploiting Autophagy to Improve Immunotherapy of Cancer, Grand Rounds, Karmanos Cancer Institute, Wayne State University, Detroit, MI, April 1, 2014
183. Exploiting Autophagy to Improve Immunotherapy of Cancer, Tocagen, San Diego, CA, April 4, 2014
184. Effective Cancer Therapies, Antibiotics and the Microbiome: A Role for Bacteriotherapy (FTP) in Improving Outcomes of Patients with Cancer? Infectious Disease City-Wide Grand Rounds, Portland, OR, April 10, 2014
185. Developing Curative Cancer Immunotherapy Approaches for the Masses: A Holistic Approach. Seminar, Department of Molecular Microbiology and Immunology Annual Retreat, Portland, OR, April 18, 2014
186. Immunoscore: Immunotherapy at a Tipping Point. Invited talk. Tumor Immunotherapy meets Oncology (TIMO), German Society for Immunology subgroup Meeting, Halle, Germany, May 22, 2014
187. Transforming the practice of oncology, Keynote address, Annual meeting of the American Academy of Caranial and Maxofacial Surgeons, Portland, Oregon, May 30, 2014
188. Autophagosome-Based Cancer Immunotherapy: DRibbles. Invited Seminar, Professorship Symposium for Tanja DeGruijl, The Free University, Amsterdam, The Netherlands, June 18, 2014

189. The Immunoscore: Strategic Considerations for the Next Decade. Invited Speaker and Co-Chair. EATI-SITC Immunoscore meeting, Paris, France, July 4, 2014
190. Immunoscore: Strategic Considerations. Invited Speaker. Association for Medical Laboratory Immunologists (AMLI), Seattle, WA, August 11, 2014
191. Cancer Immunotherapy: Scientific Breakthrough of 2013, Invited lecture, Harper Cancer Institute, Notre Dame, South Bend, IN, September 5, 2014
192. Immunoprofiling: Will It Be The "Test" To Tailor Therapies For Patients With Cancer? Invited lecture, Perkin Elmer Vectra Users Group Meeting, Boston, MA, September 9, 2014
193. The Transformation of Oncology: A strategic view of Immunoscore and Immunotherapy. SITC-CAHON-US CACA-CSCO Fourth Joint Symposium, International Track, CSCO, Xiamen, China September, 2014
194. Cancer Immunotherapy: Scientific Breakthrough of 2013. Invited seminar, National Institute of Biological Sciences, Beijing, China, September 22, 2014
195. Strategic Considerations for Immuno-Oncology Companies: Role for Vaccines. Invited seminar, Nodality, South Sanfrancisco, CA, October 6, 2014
196. Immunoscore Update. Invited talk. Annual SITC Meeting, National Harbor, MD, November 8, 2014
197. Co-stimulatory/Inflammatory Agonists, CD137, TLR3/7/8 agonists and anti-OX40-vaccine combinations. Invited talk. HNSCC Clinical Trials Planning Meeting (CTPM), NCI, NIH, Bethesda, MD, November 9-10, 2014
198. Transformation of Oncology, Schafer Memorial Lecture, Georgetown University Cancer Center, Washington, DC, December 5, 2014
199. Cancer Immunotherapy: Breakthrough of 2013 is Improving Outcomes and Curing Some Patients with Cancer. Does the Microbiome Play a Role in the Patients Who Fail to Respond? Frontiers in Biological Sciences Speaker Series, Pacific Northwest National Laboratory, Richland, WA, December 10, 2014
200. The Immunoscore and Immunoprofile: Assessing Anti-Cancer Immunity as a Biomarker to Stratify Patients and Tailor Therapy, in Trial Design Focus: Biomarkers to Predict Patient Responses to Immunotherapy, NRG Oncology Semiannual Meeting, Manchester Grand Hyatt San Diego, California February 5 – 8, 2015
201. Phenotyping Immune Cells in Solid Tumors, Molecular Med Tri-Con, Moscone North Convention Center/ InterContinental Hotel, San Francisco, CA. February 15-20, 2015
202. Strategic Considerations for Advancing Patient Outcomes with Immuno-Oncology: Role for Vaccines. Grand Rounds, St. Johns Medical Center, Santa Monica, CA, February 25, 2015
203. The Transformation of Oncology: A strategic review of Immunoscore and Immunotherapy, Keio University, Tokyo, Japan, April 22, 2015
204. The transformation of oncology: A strategic review of immunoscore and immunotherapy, Joint COS-CAHON-SITC Workshop on Cancer Immunotherapy 2015, Taipei, Taiwan, 25 April 2015
205. Integrating NGS, Immunoprofiling and Microbiome Analysis to Stratify Patients for Clinical Trials and Ultimately Tailor Immunotherapy for Patients with Cancer. Annual Oncology Symposium: Personalized Medicine, Swedish Medical Center, Seattle, WA, May 8, 2015
206. Integrating NGS, Immunoprofiling and Microbiome Analysis to Stratify Patients for Clinical Trials and Ultimately Tailor Immunotherapy for Patients with Cancer (revised title). Tumor Immunology Meets Medical Oncology (TIMO XI), German Society for Immunology and SITC, Halle, Germany, May 22-23, 2015
207. UbiVac's Immuno-Oncology Pipeline. Sachs International Immuno-Oncology Forum,

Chicago, IL, May 29, 2015

208. DRibble Immunotherapy for NSCLC, Lung Cancer Research Team (LCRT), Chicago, IL, May 29, 2015
209. Immune Biomarkers, 2015 China Cancer Immunotherapy Workshop China Center for Food and Drug International Exchange, Capital Hotel, Beijing, China, June 23, 2015
210. Immunotherapy for the Treatment of Non-Small Cell Lung Carcinoma, at SITC program: Advances in Cancer Immunotherapy™ - Dearborn, MI, July 31, 2015
211. Overview of Immuno-Oncology and its Implications for Cancer Treament, Immuno-Oncology Academy, Taipei, Taiwan, September 20, 2015
212. UbiVac's Drug Development Strategy. Oregon BioScience Association Cancer Immunotherapy BioForum, Portland, OR October 20, 2015
213. Autophagosome and Peptide Vaccines; and "Potential vaccine: vaccine and Vaccine-other combinations" Immunotherapy Conference, Hoeboken, NJ, October 23, 2015
214. Immunoscore Validation Project: Update. Presented at SITC 30th Annual Meeting, National Harbor, MD, Nov 6, 2015
215. Multispectral Imaging and Escape from Immune-Editing: A Story About Problem Relationships and Novel Intervention. At Society for Melanoma Research meeting, San Francisco, CA, November 17, 2015
216. Developing Cancer Immunotherapy Strategies that Change the Tumor Microenvironment and Eliminate Cancer. At Melanoma Bridge Meeting, Napoli, Italy, December 3rd 2015.
217. Combining Targeted Therapy with a NextGen immunotherapy: Crazy Idea or Opportunity to Convert CRs into Cures? Ignyta, San Diego, CA, December 14, 2015
218. Clinical Updates for Novel Targets and Pathways: Application of Technologies and what they tell us? 15th Annual Pep Talk, San Diego 1/18/16, San Diego 1/18/16
219. Updates and Thoughts on Current Topics in Immuno-Oncology. EACRI Institute Seminar. Portland, OR. January 29, 2016
220. Novel biomarkers: pitfalls, limitations, emerging options, at Challenges for the Approval of Anti-Cancer Immunotherapeutic Drugs, EMA-CDDF Joint Meeting, at European Medicines Agency Headquarters, London, United Kingdom, February 4-5, 2016
221. The Next Phase for Cancer Immunotherapy, Janssen Research Center, Leiden, The Netherlands, February 8, 2016.
222. Developing Treatments to Cure Patients with Cancer. Tualatin Rotary Meeting, Tualatin, OR, February 10, 2016
223. The Promise of Immunotherpy in Curing Patients with Cancer, Annual meeting of the Oncology Association of Naturopathic Physicians, Phoenix, AZ, February 28, 2016
224. Vaccines. At Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer, At Institute of Medicine, Keck Building of The National Academies of Sciences, Engineering, and Medicine, Washington, DC 20001, February 29, 2016
225. Immunotherapy at a Tipping Point, at Molecular Med TriCon, San Francisco, CA, March 10-11, 2016
226. Multispectral Imaging, at NCI-SITC Biomarkers Conference, NIH, Bethesda, MD, April 1, 2016
227. A Universal Cancer Vaccine: Alternative to Personalized Cancer Vaccine Strategies, Tumor Immunology Meets Oncology (TIMO), Halle, Germany, April 28, 2016
228. Immuno-Oncology at a Tipping Point, Bayer, Berlin, Germany, May 2, 2016
229. Recent Advances for the Immunotherapy of Advanced Cancer. Molecular Genetics Section, Taiwan Joint Cancer Conference, Taipei, Taiwan, May 14, 2016

230. The Evolving field of Immuno-Oncology, Clinical Oncology Society Section, Taiwan Joint Cancer Conference, Taipei, Taiwan, May 15, 2016
231. UbiVac, Sachs Immuno-Oncology Investor Forum, Chicago, IL, June 3, 2016
232. Impersonalization of Cancer: Development of a Universal Cancer Vaccine. Agonox Maui Meeting, Maui, HI, June 10, 2016
233. Impersonalization of Cancer: Development of a Universal Cancer Vaccine. MITR Conference University of Washington, Seattle, WA, July 18, 2016
234. Immuno-Oncology at a Tipping Point, Cardinal Bernardin Cancer Center Retreat, Loyola University, Chicago, IL, July 29, 2016
235. Novel biomarkers: pitfalls, limitations, emerging options. Presentation at Novartis site visit , Portland, OR, Sept 21, 2016
236. A Perspective on the Future of Immuno-Oncology Research. 3rd Immuno-Oncology Academy, Taipei, Taiwan, Oct 29, 2016
237. Immunoscore/Immunoprofiling and Combination Immunotherapy Including Vaccines, World Life Science Conference, Beijing, China, Nov. 2, 2016
238. Basic Biology of Immunotherapy: Cancer Vaccine, Immune Checkpoint Therapy and More. Chinese University of Hong Kong, Hong Kong, China, November 19, 2016
239. Exploiting Autophagy to Induce Broad Anti-Cancer Immunity. Immuclin Biotech, Shenzhen, China, Nov. 21, 2016
240. Multispectral Imaging. HNSCC meeting, San Diego, CA, December 10, 2016
241. Immunotherapy at a Tipping Point, Mol Med Tri-Con, San Francisco, CA, February 23, 2017
242. Antigen Presentation Defects and Cytokine Storm - Mechanisms Cancer Exploits to Escape, International Immuno-Oncology Network, London, UK, February 28, 2017
243. Immunotherapy at a Tipping Point: Preliminary Data and A Vision for Tailoring Therapy for Patients with Cancers of the Head and Neck, WECAN, Portland, OR March 11, 2017
244. Multispectral Imaging of the Tumor Environment: Focus on HPV- HNSCC, ITOC 4, Prague, CZ, March 19, 2017
245. Possible Solutions to the Biggest Hurdles for Immuno-Oncology. Sachs Venture Forum, New York, NY, March 28, 2017
246. Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures, Immuno-Oncology Combination Therapies: FDA Policy Forum, Regulatory Science and Policy Tracks at the AACR Annual Meetings http://www.abstractsonline.com/pp8/#!/4292/session/127 Washington DC, April 4, 2017
247. Immuno-Oncology at a Tipping Point. 17th Annual World Vaccine Conference, Washington DC, April 12, 2017
248. Possible Solutions to the Biggest Hurdles for Immuno-Oncology. Venture Forum, World Vaccine Conference, Washington DC, April 12, 2017
249. The Elements to Cure Cancer by Immunotherapy, Taiwan Society for Immunotherapy of Cancer, Taiwan, April 22, 2017
250. Evaluation of the Anti-Cancer Immune Response in Tumors. Definiens Syposium, Amsterdam, The Netherlands, April 25-26, 2017
251. Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans: Holbrook Kohrt, MD, PhD, Memorial Lecture, ICVI Symposium, Royal Society, London, UK, May 13, 2017
252. Hurdles to Developing Combination Immunotherapy: Insights from Preclinical Studies of Agonists Plus Checkpoint Blockade and a NextGen Approach to Characterizing Immune Cells in Human Tumors. Celldex Scientific Advisory Board Meeting, ASCO, Chicago, IL, June 5,

2017

253. NextGen Biomarkers for Precision Immunotherapy and a strategy to Impersonalize Cancer, Institute for Systems Biology (ISB) Summer Course, Seatle, WA, June 21-22, 2017
254. Development of Immunoprofiling Panels. BMS site visit, Portland, OR, USA June 29, 2017
255. Progress in Immuno-oncology: Delivering Hope and Clinical Benefit to Cancer Patients. AACR-SITC Joint Congressional Briefing. Russell Senate Office Building, Capitol Hill, Washington DC, July 19, 2017 http://www.aacr.org/AdvocacyPolicy/GovernmentAffairs/Pages/AACR-SITC-congressional-briefing.aspx?source=social&medium=Facebook&campaign=public%20affairs#.WX5nQq2ZPeQ
256. Three Important Considerations for Developing Effective Imuno-Oncology Combinations: Immunity, Co-stimulation and Checkpoint Blockade. FDA-AACR: Oncology Dose Finding Workshop Part 3, Washington DC, July 20, 2017 https://www.fda.gov/Drugs/NewsEvents/ucm562746.htm
257. How I-O Agents and Combination Therapies Change the Biomarkers: Information to Tailor Therapy. Next-Generation-Dx-Summit, Washington DC, August 18, 2017
258. Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy. Karolinska Institute, IMTAC Immunology Summer Course, Sandhamn Island, Sweden August 28-30, 2017
259. Cancer Immunotherapy: A Vision for Improving Outcomes and Increasing Cures. Radium Hospitalet, University of Oslo, Oslo, Norway. Sept 1, 2017
260. Agonistic antibodies in the era of antagonistic antibodies: monotherapy, combination and/or sequence. Sienna Consensus Conference, NIBIT and the Parker Foundation, Siena, Italy, October 7, 2017
261. Exploiting Autophagy to Induce Broad Anti-Cancer Immunity in Mice and Humans. Powering Precision Medicine. Boston, MA Oct 24, 2017
262. Update on immuno-oncology. IASLC and Taiwan Lung Cancer Society meeting, Taipei, Taiwan, October 28, 2017
263. Novel I-O Biomarkers, Multiplex IHC, and Immune Signatures. IASLC and Taiwan Lung Cancer Society meeting, Taipei, Taiwan, October 28, 2017
264. Important Questions for the EACRI/Providence - Shimadzu Collaboration. Kyoto, Japan, October 30, 2017
265. Multispectral Imaging, Cancer Vaccines, and A Strategy to Develop Combination Immunotherapy with T cell Agonists. Immunotherapy Bridge Meeting, Napoli, Italy, November 29, 2017
266. Integrating the Immunoscore into Clinical Practice: Is it Ready for Prime Time? Invited Lecture, ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, January 27, 2018
267. Development of Cancer Vaccine-Based Combination Immunotherapy Strategies to Conquer Cancer. Invited Presentation, Noble Life Science Partners Scientific Advisory Board, Ft. Lauderdale, FL, January 29, 2018
268. Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies that will Tackle the Worst Cancers. Invited lecture, University of Michigan Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, February 7, 2018
269. Opportunities and Challenges for a large health system with 40,000 new cancer patients/year to participate in the revolution that will cure cancer. SAB, Seattle, March 2, 2018
270. A Vision to Exploit NCI Prioritized Cancer Antigens and TCGA Data to Develop Combination

Immunotherapy for Rare Cancers. Keynote Address, International Workshop on Merkel Cell Carcinoma Research, Center for Cancer Research (CCR) Rare Tumor Initiative, National Cancer Institute (NCI) Shady Grove Campus, Rockville, Maryland, March 5, 2018

271. Is Immunoscore Ready for Prime Time? Definiens Headquarters, Munich, Germany, March 7, 2018
272. Immunoscore: A Brief History, Clinical Application and Strategies to Move IHC-Based Evaluations of Cancer to Stratify patients for Clinical Trials and Tailor Therapy. Invited Lecture, Thoracic Oncology Centre Munich (TOM): "State of the Art 2018" meeting, Munich, Germany, March 8 – 10, 2018
273. Exploiting Insights in Immunology and Autophagy to Develop NextGen Combination Immunotherapies. Perlmutter Cancer Center, New York University, NY, NY, March 14, 2018
274. Investigating Crucial Factors that Determine the Success of Immune Checkpoint Combinations. Immune Checkpoint Inhibition Meeting, Boston, MA, March 20-21, 2018
275. Sequencing Checkpoint Therapies. Keystone Symposia, "Cancer Immunotherapy: Combinations" Montreal, Quebec, Canada March 23-27, 2018
276. Combo immunotherapies hold great promise for better outcomes and more cures. Answer2Cancer, Portland Oregon, April 7, 2018
277. Developing NextGen Combination Immunotherapies that will Tackle the Worst Cancers. Seminar, Division of Medical Oncology, SingHealth Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 11, 2018
278. Basics of Immunotherapy with focus on role of ICI in Tolerance and Mechanism of Action. Immunotherapy Conference, Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 13, 2018
279. Future Directions: Combination Therapy and Moving to Early Stage Setting. Immunotherapy Conference, Duke/National University of Singapore Academic Medical Centre, Singapore, Singapore, April 13, 2018
280. Insights into Cancer Immunosurveillance and a Vision for Improving Patient Outcomes with Combination Immunotherapy, Grand Rounds, Oncology Center of Excellence, US FDA, White Oak, MD, April 27, 2018
281. Immunoscore Task Force: A SITC-Led Global Study. Invited lecture. Immuno-Oncology Biomarkers: State of the Art, San Francisco, CA, May 16-17, 2018
282. The Next Wave: Combination Immunotherapy with Vaccines targeting a New Class of Cancer Antigens, Combined with T cell Agonists and Checkpoint Blockers. Cambridge Health Institute Cancer Immunotherapy Meeting, Boston, MA, June 11-12, 2018
283. Why is Overall Survival Not Better For Patients Receiving Checkpoint Blockers and What Can Be Done to Improve OS? Invited lecture, Third New Horizons Head and Neck Cancer Symposium, Pittsburgh, PA, June 15-16, 2018
284. Personalizing Cancer Vaccines Is More Than Just Whole Exome Sequencing. Cambridge Health Institute, Boston, MA, August 30-31, 2018
285. Applying Advances in Genetics and Immunology to Develop Effective Immunotherapy for NSCLC Regardless of Tumor Mutational Burden.
286. Invited talk, Korean Association for Lung Cancer MSIO Conference, Imperial Palace Seoul Hotel, Seoul, Korea, October 15, 2018
287. Cancer Vaccines: Current and Perspective Challenges. Invited talk, Siena Consensus Conference. Siena, Italy October 25, 2018
288. The Cancer-Host Interface: What Can It Tell Us? Invited talk in NanoString session, Association for Molecular Pathology, Austin, Texas, October 30, 2018

289. Cancer vaccines and strategy to develop combination immunotherapy with T cell agonists. Invited talk, Immunotherapy Bridge Conference, Napoli, Italy, December 6, 2018
290. Agonist immunomodulatory monoclonal antibodies: Sequencing and Optimizing Combinations. Invited speaker ESMO I-O, Geneva, Switzerland, December 15, 2018
291. New Immune-Based Predictive Biomarkers and New Combinations of Immune Checkpoint Modulators. Invited talk. Marseille Immunopole, Marseille, France, January 16, 2019
292. Evolving Concepts of Anticancer Immunity that May Help to #FinishCancer. Invited talk, A Deeper Dive – the Agonox Maui Meeting. The Fairmont Hotel, Maui, Hawaii, February 28, 2019
293. Possible use of Immunoprofiling to stratify or direct Combination Immunotherapy. Invited talk. Cambridge Healthcare Institute TriCon Conference on Cancer Immunotherapy. San Francisco, California, March 11-13, 2019
294. Latest Trends for Multi-Omics Integration in Combination Immunotherapy Trials. Invited talk in Definiens #INSPIRE SERIES2019, satellite session of AACR. Atlanta, Georgia, March 31, 2019
295. Combination Immunotherapy with Vaccines Targeting a New Class of Cancer Antigens, Combined with T cell Agonists and Checkpoint Blockers. Invited talk, The Future of Health: Concept to Clinic, an Institute for Systems Biology Conference. Seattle, Washington. April 8, 2019
296. Strategies to monitor and optimize costimulatory effects of T cell agonists and rescue them from the dustbin of failed single agents. Invited talk, Tumor Immunology Meets Oncology (TIMO), Halle, Germany, April 26-27, 2019
297. Cancer Immunotherapy in Evolution: Vaccination, Co-stimulation and Checkpoint Blockade. Invited talk, 4th International Conference on Immunotherapy, organized by ICVI. The Royal Society, London, UK, May 24-25, 2019
298. Cancer Immunotherapy: Insights from the past and a vision for the future. Invited talk, Translational Immunology Lecture, Else-Kroner-Foschungskolleg, Wurzburg, Germany, June 28, 2019
299. Strategies to monitor and optimize cancer immunotherapy (proposed). Invited talk, Cancer and Microenvironment Interaction Conference, Taipei, Taiwan, July 6, 2019

SELECTED ABSTRACTS, PRELIMINARY COMMUNICATIONS, PANEL DISCUSSIONS

Preliminary Communications and Reports:
Report on Gene Transfer into Human TIL and into Animal Models. Prepared for the Human Gene Therapy Subcommittee by: R.M. Blaese with data provided by: P. Abersold, F. Anderson, K. Cornetta, K. Culver, M. Daucher, M. Feller, **B. Fox**, S. Freeman, A. Stephens, A. Kasid, M. Lotze, B. Moen, S. Morecki, R. Morgan, N. Nguyen, and S. Rosenberg, November 23, 1988.

**Panel Discussions, Workshops and Conferences:**

Co-Chaired Adoptive Immunotherapy Session, with Dr. P.S. Mitrou, Frankfurt International Interleukin-2 Symposium, March 24, 1990, Frankfurt, Germany.

Organizer and Chairperson, Fourth Annual American Cancer Society Research Conference, September 24, 1993, Towsley Center, University of Michigan, Ann Arbor, MI

Organizer and Co-Chairperson, First Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, July 25, 1995, UCSF Cancer Center, Mount Zion Hospital, San Francisco, CA.

Organizer and Co-Chairperson, Second Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 20, 1996, Washington, D.C..

Organizer and Co-Chairperson, Third Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 12, 1997, San Diego, CA.

Organizer and Co-Chairperson, Satellite meeting of the Tumor Vaccine and Cell Therapy Working Group, March 28, 1998, Tulane University, New Orleans, LA

Organizer and Co-Chairperson, Fourth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 18, 1998, San Francisco, CA.

Co-moderator with Dr. Phil Nogochi Session III in FDA/NCI Autologous and Allogeneic Tumor cells as Vaccines, Workshop on Tumor vaccines, Mazur Auditorium, NIH Bethesda, MD

Organizer and Co-Chairperson, Fifth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 10, 1999, Philadelphia, PA.

Organizer and Co-Chairperson, Sixth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 1, 2000, San Francisco, CA.

Co-Organizer with Michael Widmer and John Thompson, Fifteenth Annual meeting of the Society for Biological Therapy, October 26-29, 2000 Seattle, WA

Organizer and Co-Chairperson, Seventh Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, March 24, 2001, New Orleans, LA.

Co-Chairperson. Effector Mechanisms mini-symposia, Annual meeting of the American Association of Immunologists, March 31 –April 4, 2001, Orlando, FL.

Organizer and Co-Chairperson, Eight Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 5, 2002, San Francisco, CA.

Organizer and Co-Chairperson, The first Tegernsee Conference on Immunotherapy of Solid Cancers. July 3-5, 2002, Tegernsee, Germany (http://www.tegernsee-conference.de/.)

Co-Chairperson, Development of Therapeutic Cancer Vaccines, April 27-29, 2003, Los Angeles, CA.

Panelist, The future of Gene Therapy in Healthcare –HealthTech Conference, July 29, 2003, San Francisco, CA.

Member Scientific Committee, 7th International Meeting and 1st World Congress Biotherapy of Cancer - From Disease to Targeted Treatment, September 10-13, 2003, Munich, Germany (http://tzm.web.med.uni-muenchen.de/btoc/)

Program Committee. Strategies for early clinical development of Molecular Targeted Therapy of Cancer, March 17, 2004, Innsbruck, Austria.

Organizer and Co-Chairperson, Tenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, March 26, 2004, Orlando, FL.

Co-Chairperson. Adoptive Immunotherapy session, International Society for Biological Therapy of Cancer, November 5, 2004, San Francisco, CA.

Organizer and Co-Chairperson, Eleventh Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, April 15, 2005, Anaheim, CA.

Organizer and Co-Chairperson, The Second Tegernsee Conference on Immunotherapy of Solid Cancers, June 29 – July 2, 2005, Tegernsee, Germany (http://www.tegernsee-conference.de/.)

Organizer and Co-Chairperson, 12th Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, March 31, 2006, Washington DC.

Scientific Advisor. 8th International Symposium from Disease to Targeted Therapy co-organized by Biotherapy Development Association, European Society for Medical Oncology and the National Cancer Institute, June 21 – 24, 2006, Dresden, Germany,

Chairperson. National Development Event for chairs of Urology. July 7-8, 2006, Baltimore, MD.

Program Committee. "Combination Therapy for Cancer: Opportunities and Obstacles for Future Development". International Society for Biological Therapy of Cancer Workshop, July 29, 2006. Rockville, MD.

Chairperson, Advances in murine melanoma models session. Perspectives in Melanoma X, Society for Melanoma Research and European Organization for the Research and Treatment of Cancer, September 14-16, 2006, Noordwijk, The Netherlands,

Chairperson. Combination Therapy for Cancer: Opportunities and Obstacles for Future Development. International Society for Biological Therapy of Cancer, October 26-29, 2006, Rockville, MD

Co-Chairperson. Immunotherapeutic, Monoclonal Antibodies & Translational Medicine, Society for Biomolecular Sciences Conference. April 14-19, 2007. Montreal, Canada

Organizer and Co-Chairperson, Thirteenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, Satellite meeting to International Congress of Immunology, August 9 – 11, 2007, Rio De Janeiro.

Organizer, Workshop on Future Opportunities for Combination Biological Therapy of Cancer. http://www.isbtc.org/meetings/workshop07/ November 1, 2007 - Boston, MA

Co-Organizer: Hot Topic Session: "Dendreon Debate". International Society for Biological Therapy of Cancer. November 4, 2007 - Boston, MA
http://www.isbtc.org/news/releases/112807.php

Scientific Advisor. 9th International Symposium from Disease to Targeted Therapy co-organized by Biotherapy Development Association, European Society for Medical Oncology, iSBTc and the National Cancer Institute, www.bdaoncology.org Munich, Germany, March 12 – 14, 2008

Organizer and Co-Chairperson, Fourteenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, San Diego, CA, April 11, 2008

Co-Organizer: Hot Topic Symposium: Anti-CTLA-4: Issues in Development and Regulatory Approval. International Society for Biological Therapy of Cancer. , San Diego, CA, Oct. 29, 2008
http://www.isbtc.org/meetings/am08/symposium/

Participant, iSBTc Clinical Endpoint and Response Criteria Working Group. San Diego, CA, November 1, 2008.

Co-Chair. 12th US-Japan Cellular and Gene Therapy conference on Immune Regulation, FDA, Bethesda, MD. February 26, 2009

Organizer and moderator, "Converging Concepts in Cell Therapy", National Heart Lung and Blood Institute Workshop, NIH. Bethesda, MD, April 23-24, 2009.

Organizer and Co-Chairperson, Fifteenth-A Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, Denver, CO, pre AACR, 2009

Organizer and Co-Chairperson, Fifteenth –B, Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, Seattle, WA, pre-AAI, May 8, 2009

Co-Organizer: The 3rd Tegernsee Conference on Immunotherapy of solid cancer, Tegernsee, Germany, July 1-3, 2009. http://www.tegernsee-conference.de/

Organizing / planning Committee/ iSBTc representative: FDA-NCI Vaccine Conference, Washington DC, October 27, 2009.

Steering Committee: iSBTc-FDA Taskforce on Immunotherapy Biomarkers. Workshop, Washington DC, October 28, 2009.
http://www.isbtc.org/news/enews.php#Taskforce

Organizer and Co-Chairperson, Sixteenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, Kobe, Japan, satellite of ICI, 2010

Organizer and Co-Chairperson, Seventeenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, University of California, San Francisco (UCSF), SanFrancisco, California, satellite of AAI, 2011

Co-Organizer and Co-Chairperson, Cancer Immunotherapy CSCO-SITC-CAHON Joint Symposium. The 14th CSCO Annual Meeting, Xiamen, September 14-16, 2011.

Scientific Committee. Melanoma Research, A Bridge from Naples to the World. Napoli, Italia, December 5-6th, 2011

Organizing and planning Committee, World Immunotherapy Council Inaugural Summit, Curacao, February 21st – 24th, 2012

Co-Chair with Dr. Michael Nishimura, Eighteenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, LUMC, Chicago, Il, satellite of AACR, 2012

Co-Organizer and Co-Chairperson, Cancer Immunotherapy CSCO-SITC-CAHON Joint Symposium. The 15th CSCO Annual Meeting, Beijing, China, September 20 - 24, 2012.

Scientific Committee. Melanoma Bridge and World Immunoscoring Meeting 2012, Naples, Italy, December 2-4, 2012

Chair, Immunotherapies and Cancer Vaccines session- CQ3486, Brussels, Belguim, December 7th, 2012

Co-Organizer with Dr. Michael Nishimura, Nineteenth Annual meeting of the Tumor Vaccine and Cell Therapy Working Group, University of Hawaii, Honolulu Cancer Center, satellite of AAI, May 3, 2013

Co-Organizer (did not attend), Cancer Immunotherapy CSCO-SITC-CAHON Joint Symposium. The 16th CSCO Annual Meeting, Xiamen, China, September 20 - 24, 2013.

Organizer, World Immunotherapy Council (WIC) meeting, Milan, Italy, August 25, 2013

Organizing Committee and Co-Chair Immunoscore Session (with Dr. Jerome Galon). SITC-SIDRA Symposium on Immunoscore 2014, Doha, Qatar, January 22-23, 2014
http://sidra.org/events/event/updates-on-immunotherapy-of-cancer-and-immunoscore/

Plenary Session Co-Chair (with Dr. L. Hakansson): Monitoring of Immunotherapy. ITOC – Immunotherapy of Cancer, Biotherapy Development Association (BDA), European CanCer Organisation (ECCO), Hörsaal A, Klinikum rechts der Isar, Technical University – TU, Munich, Germany, March 12-14, 2014

Session Co-Chair, Future Prospects of Immunoscore (with Dr. Franck Pagès). In, Natural and Therapy Induced AntiCancer Immunosurveillance: The Immunoscore. Miltenyi Biotec, European Academy of Tumor Immunology, 8eme Journees scientifiques Miltenyi Biotec, Paris, France, July 3-4, 2014

Co-Chair, Cancer Immunotherapy, SITC-CAHON-US CACA-CSCO Joint Symposium. International Track Program, Chinese Society for Clinical Oncology (CSCO). Xiamen, China, September 17-21, 2014

Plenary Session Co-Chair (with Dr. Volker Heinemann): Combination Immunotherapy. ITOC –2 Immunotherapy of Cancer Conference, European CanCer Organisation (ECCO), Munich, Germany, March 25-27, 2015

Co-organizer/SITC Representative, Joint COS-CAHON-SITC Workshop on Cancer Immunotherapy 2015, Taipei, Taiwan, 25 April 2015

Co-Chair (with Dr. Robert Binder, U. Pittsburgh), New Cancer Vaccines Symposium, American Association of Immunologists (AAI), New Orleans, LA, May 11, 2015

Co-Chair (with Prof. Michele Maio, Sienna) Novel Immunotherapy Strategies, Tumor Immunology Meets Medical Oncology (TIMO XI), German Society for Immunology and SITC, Halle, Germany, May 22-23, 2015

Co-Chair (with Prof. Zhigang Tian) session on Cancer Immunotherapy at World Life Science Conference, Beijing, China, Nov. 2nd 2016

Panel Discussion: FDA Policy Forum, Regulatory Science and Policy Tracks at the AACR Annual Meetings, Washington DC, April 4, 2017

Presenter and panelist: At AACR-SITC Joint Congressional Briefing. Russell Senate Office Building, Capitol Hill, Washington DC, July 19, 2017

Presenter and panelist: At FDA-AACR: Oncology Dose Finding Workshop Part 3, Washington DC, July 20, 2017

Presenter and panelist: At Sienna Consensus Conference, NIBIT and the Parker Foundation, Siena, Italy, Oct 7, 2017

Scientific Board: Immunotherapy and Melanoma Bridge 2017, Naples, Italy, November 29 – December 2, 2017

Presenter and panelist: Panel Discussion, ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA, January 27, 2018

Discussant: Panel Discussion (Chair, Dr. James J. Mule'), Cancer Immunotherapy Strategies to Conquer Cancer. Noble Life Science Conference 14 (NobleCon14), Ft. Lauderdale, FL, January 29, 2018

Workshop Participant: International Workshop on Merkel Cell Carcinoma Research (IWMCC), Sponsored by: Rare Tumor Initiative, NCI, NIH, NIAMS, NIH, and Department of Pathology, University of Michigan. National Cancer Institute (NCI) Shady Grove Campus, Rockville, Maryland, March 5, 2018

Workshop Participant: The cytokine network and its interaction with cellular immunity. At Thoracic Oncology Centre Munich (TOM): "State of the Art 2018" meeting, Munich, Germany, March 7 – 10, 2018

Meeting Chair, Immune Checkpoint Inhibition Meeting, Boston, MA, March 20-21, 2018

Co-Chair: Cancer Immunotherapy, SITC Guest Symposium at the American Association of Immunologists (AAI) Annual meeting, Austin, TX, May 5, 2018,

Co-Chair session on Cancer Vaccines at The Siena Consensus Conference, Siena, Italy, October 25, 2018.

Co-Chair session on Biomarkers at Society for Immunotherapy of Cancer (SITC) annual meeting, Washington, DC, November 9, 2018

Co-Chair session on Combination Immunotherapy of Cancer at ESMO I-O meeting, Geneva, Switzerland, December 16, 2018.

Scientific Committee Chairman: Profs. Zhigang Tian and Bernard A. Fox, Satellite Conference on Cancer Immunotherapy of IUIS and International Congress of Immunology, Hefei, China, October 20-22, 2019